key: cord-0714617-iu5ndsxn authors: Popp, Maria; Stegemann, Miriam; Metzendorf, Maria-Inti; Gould, Susan; Kranke, Peter; Meybohm, Patrick; Skoetz, Nicole; Weibel, Stephanie title: Ivermectin for preventing and treating COVID‐19 date: 2021-07-28 journal: Cochrane Database Syst Rev DOI: 10.1002/14651858.cd015017.pub2 sha: 66f13371edcd76257c1b40b77caa7dae60ca6368 doc_id: 714617 cord_uid: iu5ndsxn BACKGROUND: Ivermectin, an antiparasitic agent used to treat parasitic infestations, inhibits the replication of viruses in vitro. The molecular hypothesis of ivermectin's antiviral mode of action suggests an inhibitory effect on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) replication in the early stages of infection. Currently, evidence on efficacy and safety of ivermectin for prevention of SARS‐CoV‐2 infection and COVID‐19 treatment is conflicting. OBJECTIVES: To assess the efficacy and safety of ivermectin compared to no treatment, standard of care, placebo, or any other proven intervention for people with COVID‐19 receiving treatment as inpatients or outpatients, and for prevention of an infection with SARS‐CoV‐2 (postexposure prophylaxis). SEARCH METHODS: We searched the Cochrane COVID‐19 Study Register, Web of Science (Emerging Citation Index and Science Citation Index), medRxiv, and Research Square, identifying completed and ongoing studies without language restrictions to 26 May 2021. SELECTION CRITERIA: We included randomized controlled trials (RCTs) comparing ivermectin to no treatment, standard of care, placebo, or another proven intervention for treatment of people with confirmed COVID‐19 diagnosis, irrespective of disease severity, treated in inpatient or outpatient settings, and for prevention of SARS‐CoV‐2 infection. Co‐interventions had to be the same in both study arms. We excluded studies comparing ivermectin to other pharmacological interventions with unproven efficacy. DATA COLLECTION AND ANALYSIS: We assessed RCTs for bias, using the Cochrane risk of bias 2 tool. The primary analysis excluded studies with high risk of bias. We used GRADE to rate the certainty of evidence for the following outcomes 1. to treat inpatients with moderate‐to‐severe COVID‐19: mortality, clinical worsening or improvement, adverse events, quality of life, duration of hospitalization, and viral clearance; 2. to treat outpatients with mild COVID‐19: mortality, clinical worsening or improvement, admission to hospital, adverse events, quality of life, and viral clearance; (3) to prevent SARS‐CoV‐2 infection: SARS‐CoV‐2 infection, development of COVID‐19 symptoms, adverse events, mortality, admission to hospital, and quality of life. MAIN RESULTS: We found 14 studies with 1678 participants investigating ivermectin compared to no treatment, placebo, or standard of care. No study compared ivermectin to an intervention with proven efficacy. There were nine studies treating participants with moderate COVID‐19 in inpatient settings and four treating mild COVID‐19 cases in outpatient settings. One study investigated ivermectin for prevention of SARS‐CoV‐2 infection. Eight studies had an open‐label design, six were double‐blind and placebo‐controlled. Of the 41 study results contributed by included studies, about one third were at overall high risk of bias. Ivermectin doses and treatment duration varied among included studies. We identified 31 ongoing and 18 studies awaiting classification until publication of results or clarification of inconsistencies. Ivermectin compared to placebo or standard of care for inpatient COVID‐19 treatment We are uncertain whether ivermectin compared to placebo or standard of care reduces or increases mortality (risk ratio (RR) 0.60, 95% confidence interval (CI) 0.14 to 2.51; 2 studies, 185 participants; very low‐certainty evidence) and clinical worsening up to day 28 assessed as need for invasive mechanical ventilation (IMV) (RR 0.55, 95% CI 0.11 to 2.59; 2 studies, 185 participants; very low‐certainty evidence) or need for supplemental oxygen (0 participants required supplemental oxygen; 1 study, 45 participants; very low‐certainty evidence), adverse events within 28 days (RR 1.21, 95% CI 0.50 to 2.97; 1 study, 152 participants; very low‐certainty evidence), and viral clearance at day seven (RR 1.82, 95% CI 0.51 to 6.48; 2 studies, 159 participants; very low‐certainty evidence). Ivermectin may have little or no effect compared to placebo or standard of care on clinical improvement up to 28 days (RR 1.03, 95% CI 0.78 to 1.35; 1 study; 73 participants; low‐certainty evidence) and duration of hospitalization (mean difference (MD) −0.10 days, 95% CI −2.43 to 2.23; 1 study; 45 participants; low‐certainty evidence). No study reported quality of life up to 28 days. Ivermectin compared to placebo or standard of care for outpatient COVID‐19 treatment We are uncertain whether ivermectin compared to placebo or standard of care reduces or increases mortality up to 28 days (RR 0.33, 95% CI 0.01 to 8.05; 2 studies, 422 participants; very low‐certainty evidence) and clinical worsening up to 14 days assessed as need for IMV (RR 2.97, 95% CI 0.12 to 72.47; 1 study, 398 participants; very low‐certainty evidence) or non‐IMV or high flow oxygen requirement (0 participants required non‐IMV or high flow; 1 study, 398 participants; very low‐certainty evidence). We are uncertain whether ivermectin compared to placebo reduces or increases viral clearance at seven days (RR 3.00, 95% CI 0.13 to 67.06; 1 study, 24 participants; low‐certainty evidence). Ivermectin may have little or no effect compared to placebo or standard of care on the number of participants with symptoms resolved up to 14 days (RR 1.04, 95% CI 0.89 to 1.21; 1 study, 398 participants; low‐certainty evidence) and adverse events within 28 days (RR 0.95, 95% CI 0.86 to 1.05; 2 studies, 422 participants; low‐certainty evidence). None of the studies reporting duration of symptoms were eligible for primary analysis. No study reported hospital admission or quality of life up to 14 days. Ivermectin compared to no treatment for prevention of SARS‐CoV‐2 infection We found one study. Mortality up to 28 days was the only outcome eligible for primary analysis. We are uncertain whether ivermectin reduces or increases mortality compared to no treatment (0 participants died; 1 study, 304 participants; very low‐certainty evidence). The study reported results for development of COVID‐19 symptoms and adverse events up to 14 days that were included in a secondary analysis due to high risk of bias. No study reported SARS‐CoV‐2 infection, hospital admission, and quality of life up to 14 days. AUTHORS' CONCLUSIONS: Based on the current very low‐ to low‐certainty evidence, we are uncertain about the efficacy and safety of ivermectin used to treat or prevent COVID‐19. The completed studies are small and few are considered high quality. Several studies are underway that may produce clearer answers in review updates. Overall, the reliable evidence available does not support the use ivermectin for treatment or prevention of COVID‐19 outside of well‐designed randomized trials. (1 RCT) We are uncertain whether ivermectin may increase or reduce any adverse events up to 28 days No studies reported quality of life up to 28 days. The mean duration of hospitalization in the placebo group was 9.7 days The mean duration of hospitalization in the ivermectin group was 0. We are uncertain whether ivermectin increases or reduces viral clearance at 7 days. e Downgraded one level for serious risk of bias and one level for serious imprecision due to few participants. Another study reported data as medians that were not eligible for meta-analysis. The median duration of hospitalization in the ivermectin group was six days (interquartile range (IQR) 4 to 11 days) compared to five days (IQR 4 to 7 days) in the placebo group. f Downgraded one level for serious risk of bias, one level for serious heterogeneity (I 2 = 77%), and two levels for very serious imprecision due to few participants and wide CIs. We included studies at high risk of bias in a secondary analysis (RR 1.19, 95% CI 0.76 to 1.86). Summary of findings 2. Ivermectin compared to placebo or standard of care for people with mild COVID-19 treated in an outpatient setting Ivermectin compared to placebo or standard of care for people with mild COVID-19 treated in an outpatient setting Patient or population: people with mild disease (WHO scale 1-3); all studies contributing results to the summary of findings We are uncertain whether ivermectin increases or reduces viral clearance at 7 days. Ivermectin compared to no treatment for prevention of SARS-CoV-2 infection Patient or population: people who were not infected with SARS-CoV-2, but were at high risk of developing the infection (e.g. after high-risk exposure) Comparison: no treatment -----a No study with low risk or some concerns of bias reported development of clinical COV-ID-19 symptoms up to 14 days. No study with low risk or some concerns of bias reported adverse events up to 14 days. 1 study assessed all-cause mortality during the study period, but 0 participants in either group died (Shoumann 2021). Not estimable 304 (1 RCT) We are uncertain whether ivermectin reduces or increases all-cause mortality up to 28 days. -----No study reported admission to hospital up to 14 days. Data on mortality substantially di er between locations, depending on the population structure, the case-mix of infected and deceased individuals, other local factors, and changes during the ongoing outbreak. With an inhospital mortality for people receiving ventilation of over 70% (Karagiannidis 2020), the patients who survive o en have considerable consequential damage (Herrmann 2020; Prescott 2020). COVID-19 can lead to death due to a variety of causes, such as severe respiratory failure, septic shock, and multiple organ failure (WHO 2020a). The case-fatality ratio worldwide is currently estimated at 2.2% with large statistical fluctuations (less than 0.1% in Singapore up to almost 20% in Yemen; status July 2021) (Dong 2020). However, these varying rates should not be interpreted as markers for the quality of health care (Karagiannidis 2020), or the aggressiveness of di erent virus variants. These statistics are influenced by the mean age of a population or of those infected, the quality and extent of local test strategies, and documentation and reporting systems (Kobayashi 2020). The gold standard for confirming a SARS-CoV-2 infection is the reverse transcription polymerase chain reaction (RT-PCR)-based detection of viral ribonucleic acid (RNA) from a nasopharyngeal swab test, sputum, or tracheal secretion, with a sensitivity ranging from 70% to 98%, depending on pretest probability (Watson 2020). O ering lower sensitivity but greater practicality and accessibility, antigen tests are receiving increased attention, especially in point-of-care diagnostics of COVID-19 (WHO 2020c). Transmission is typically inferred from population-level information. Inherent properties of virus variants of concern, and individual di erences in infectiousness among individuals or groups make it di icult to contain its spread in the community (WHO 2021a) . Currently, the most e ective and ubiquitously available measures to control virus spreading are non-pharmaceutical interventions, including physical distancing, wearing a facemask, especially when distancing cannot be maintained, keeping rooms well ventilated, avoiding crowds and close contact, regularly cleaning your hands, and coughing into a bent elbow or tissue. Research on prophylaxis of SARS-CoV-2 infection and treatment of COVID-19 is being carried out under great pressure worldwide. Evaluating the e ectiveness of repurposed drugs represents one important strand of these research e orts. In this context, ivermectin -an antiparasitic intervention -has received substantial attention, especially in South America and parts of Asia. Ivermectin is an antiparasitic agent belonging to the group of avermectins, originally a fermentation metabolite produced by the bacterium Streptomyces avermitilis. Ivermectin was introduced for medical use in 1982 and is e ective against various types of nematodes and helminths, and ectoparasites such as mites and lice. The mode of action is based on binding to specific cell membrane channels that only occur in invertebrates. Channel activation ultimately leads to blocked cell signal transmission through chloride-induced hyperpolarization. Consequently, parasites are paralysed and die, interrupting their reproduction cycle (Campbell 1983; Dourmishev 2005; Panahi 2015) . Ivermectin is on the WHO List of Essential Medicines for its high e ectiveness against human ectoparasite infestations (WHO 2019). In animals and humans, ivermectin is easily resorbed by the mucosa if taken orally or the skin if taken topically. As a lipophilic compound, it accumulates in fat and liver tissue from where it e uses and takes e ect. Elimination is processed through bile and faeces. Ivermectin is widely used in veterinary medicine, but it is also approved for human parasitic diseases such as onchocerciasis, lymphatic filariasis, strongyloidiasis, and scabies in several countries (e.g. the USA, Japan, France, Germany, Australia) (González-Canga 2008) . The established dosing regimen ranges from 150 µg/kg to 200 µg/kg administered orally, with a one-to twodose administration generally being e ective. Dosing is generally low because of the agent's high potency (Ashour 2019). Adhering to recommended doses, ivermectin is generally well tolerated. Adverse e ects -which seem to arise partially from the rapid death of parasites, leading to hyperinflammation and anaphylactic reactions -include weakness, drowsiness, diarrhoea, nausea, and vomiting. In addition, ivermectin can cause fever and rash. Rare serious adverse e ects can occur, such as vision problems, neurotoxicity, and liver damage (González-Canga 2008) . One in vitro study showed that ivermectin can inhibit replication of the human-immunodeficiency-virus 1 (HIV-1), via inhibition of the interaction of virus proteins and a human cargo protein complex called importin (IMPα/β1) (Wagsta 2012). Importin is used by viruses for nuclear import in order to initiate their replication process (Wagsta 2012 Cochrane Database of Systematic Reviews inhibitory potential for virus replication in vitro, there is no evidence of clinical e ectiveness to date. Before the COVID-19 pandemic, only two clinical trials had been registered on ClinicalTrials.gov (clinicaltrials.gov/) using ivermectin as an intervention for treatment of virus diseases. Only one of these had published results (Yamasmith 2018) . In this small, single-centre study published as a conference abstract, ivermectin showed a shorter viral protein clearance time compared to placebo in people infected with dengue virus (Yamasmith 2018). Another member of the beta-coronavirus family, SARS-CoV-1, which also causes respiratory failure, revealed similar dependence on the IMPα/β1 interaction (Wulan 2015) . The pathogen causing COVID-19, SARS-CoV-2, is also an RNA virus closely related to SARS-CoV-1. In 2020, ivermectin gained high interest as a promising therapeutic option against SARS-CoV-2, when Caly 2020 published their experimental study results showing that ivermectin inhibits the replication of SARS-CoV-2 in cell culture. So far, the only drugs shown to be clearly e ective in COVID-19 treatment are targeting the immune response to a SARS-CoV-2 infection; for example, dexamethasone (RECOVERY 2021) . Therefore, ivermectin's potential to restrict the disease's progression, or even its outbreak, indicates that it is possibly an e ective antiviral agent. However, until showing success in human clinical trials with patient-relevant outcomes, these findings remain suggestive. The molecular hypothesis of ivermectin's antiviral mode of action, explained above, suggests an inhibitory e ect on virus replication in the early stages of the disease, indicating a benefit especially for people with mild or moderate disease. This has also led to the idea of the possible preventive potency of ivermectin on infection with SARS-CoV-2 in individuals a er exposure to a contagious contact, called postexposure prophylaxis. In response to the early promising in vitro studies on ivermectin, mentioned above, several COVID-19 clinical trials have been initiated to investigate the prophylactic and therapeutic e ects of ivermectin. Ivermectin is an inexpensive and widely used medicine, mainly in low-and middle-income countries with a high burden of parasitic diseases. The recently published in vitro studies, especially the results of Caly 2020, have led to great interest in ivermectin in many countries with high numbers of SARS-CoV-2 infections, including the USA and countries of South America and Asia. In South America in particular, people started liberally self-medicating with ivermectin, and the drug has become part of public health policies without reliable scientific data. For example, in May 2020, Bolivian and Peruvian health o icials recommended ivermectin for the treatment of COVID-19 without supplying evidence. In Brazil, it was promoted as a preventive measure by municipalities (Rodríguez-Mega 2020) . Due to the rapid increase in interest in ivermectin and the risk of abuse, the US Food and Drug Administration (FDA) discouraged the use of ivermectin intended for animals (FDA 2020). The increased research interest in ivermectin has led to the registration of numerous trials in clinical trials registries worldwide. As of 2 July 2021, there were 73 trials registered on ClinicalTrials.gov (clinicaltrials.gov/) investigating ivermectin in various settings. Several studies describe ivermectin's positive e ect on resolution of mild COVID-19 symptoms or describe a reduction of inflammatory marker levels or shorter time to viral clearance, while other studies indicate no e ect or even a negative e ect on disease progression. Many studies are already summarized in existing systematic reviews, meta-analyses, and guidelines (Bryant 2021; Hill 2021; NIH 2021) . It has to be kept in mind that many available meta-analyses and reviews, as well as most of the underlying original studies, have not yet been published in peer-reviewed journals and are only available on preprint servers without any supervising authority. Given the pace of the pandemic, it is important and welcome to make new scientific findings immediately available. But non-peer-reviewed results have to be handled with care and should not be used as the sole basis for clinical decisions and recommendations. Methodological limitations in the design of original studies, data integrity, and potential conflicts of interests have to be critically appraised when judging trial results. Many reviews and meta-analyses of ivermectin for COVID-19 are not reliable due to insu icient methodological accuracy and quality. As of July 2020, the e icacy and safety of ivermectin for COVID-19 treatment and prophylaxis are still subject to debate. The most recent Association of the Scientific Medical Societies in Germany (AWMF) guideline recommends against the use of ivermectin as antiviral treatment (German AWMF Guideline 2021), while in February 2021, the US National Institutes of Health (NIH) revised their COVID-19 treatment guidelines from a recommendation 'against the use of ivermectin' to 'cannot recommend either for or against the use of ivermectin,' giving clinicians leeway in individual case decision-making (NIH 2021) . The WHO recommends that the drug only be used within clinical trials as current evidence on the use of ivermectin to treat people with COVID-19 is inconclusive (WHO 2021b) . This review aimed to provide a complete evidence profile, based on current Cochrane standards, for ivermectin with regard to e icacy and safety for postexposure prophylaxis and treatment of COVID-19. To assess the e icacy and safety of ivermectin compared to no treatment, standard of care, placebo, or any other proven intervention for people with COVID-19 receiving treatment as inpatients or outpatients, and for prevention of an infection with SARS-CoV-2 (postexposure prophylaxis). We included randomized controlled trials (RCTs) only, as this is the best study design for evaluating the e icacy of interventions (Higgins 2020a). Non-standard RCT designs, such as clusterrandomized and cross-over trials, were not eligible for the review (Higgins 2020b). These designs are not appropriate in this context, since the underlying cause of COVID-19 is an infection with the SARS-CoV-2 virus and the medical condition evolves over time. We included full-text journal articles published in PubMedindexed and non-indexed journals, preprint articles, results published in trial registers, and abstract publications. All studies, especially preprint articles that have not been peer-reviewed, Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews must have reported robust and valid data on study design, participants' characteristics, interventions, and outcomes, to be eligible for inclusion. We categorized studies in question as 'awaiting classification' until the authors publish further information or clarify certain questions. We applied no restrictions on the language of publication of the articles. We included studies investigating participants with confirmed SARS-CoV-2 infection (RT-PCR or antigen testing), regardless of age, gender, ethnicity, disease severity, and setting (inpatients and outpatients). If studies included participants with a confirmed or suspected COVID-19 diagnosis, we used only the data for the patient population with confirmed COVID-19 diagnosis. In cases, where data were not reported separately for people with confirmed or suspected COVID-19 diagnosis, we excluded the study. We included studies investigating participants who were not infected with SARS-CoV-2 at enrolment, but were at high risk of developing the infection (e.g. a er high-risk exposure), regardless of age, gender, ethnicity, disease severity, and setting (inpatient and outpatients). Participants may have been hospitalized for reasons other than COVID-19. Eligible trials must have reported the history of previous SARS-CoV-2 infections or serological evidence in included participants. A history of SARS-CoV-2 infection was not an exclusion criterion. We excluded studies investigating ivermectin for prevention and treatment of other viral diseases. All doses and regimens of ivermectin were eligible and pooled for the primary analysis. Dosing schemes were considered and categorized into low (up to 0.2 mg/kg orally, single dose) and high doses (greater than 0.2 mg/kg orally, single dose or with higher frequency). We planned to analyse di erent doses in subgroup analyses, if su icient studies are available for review updates. We compared ivermectin to no treatment, standard of care, or placebo. Co-interventions (standard of care) must have been comparable between the study arms, i.e. ivermectin plus standard of care versus standard of care. We planned to compare ivermectin to any other active pharmacological comparator with proven e icacy for prevention or treatment of COVID-19. For dexamethasone, it has been shown that mortality from COVID-19 was lower among people who were randomized to receive dexamethasone than among those who received the usual standard of care (RECOVERY 2021; Siemieniuk 2020) . Remdesivir showed some benefit for people hospitalized with COVID-19, though to a lesser extent (Beigel 2020). Therefore, dexamethasone and remdesivir will be considered eligible active comparators for review updates. For patients that qualify for (for example) dexamethasone therapy or for another intervention that proves to be beneficial in the future, it would be unethical to further conduct trials that use placebo only. In contrast, studies using comparators (e.g. hydroxychloroquine) without proven e icacy may confound the assessment of the e icacy or safety of ivermectin and were excluded. Although those types of interventions were possibly used at a certain point of time during the pandemic with the best intentions, their use was never supported by actual evidence, and they have potential adverse e ects (Singh 2021). From those comparisons, no reliable evidence can be obtained. Studies investigating various concomitant medications (e.g. doxycycline, hydroxychloroquine, azithromycin, zinc) in addition to ivermectin or as comparator drug were not eligible for this review. Due to unproven e icacy, possible adverse e ects, and drug interactions, these comparisons may confound the assessment of the e icacy or safety of ivermectin. We created these comparisons: • ivermectin versus no treatment, placebo, or standard of care; and • ivermectin versus active pharmacological intervention with proven e icacy (no studies available for the current review version). We analyzed di erent outcomes for the use of ivermectin for treatment of people with COVID-19 in inpatient and outpatient settings, and for the prevention of SARS-CoV-2 infection. If studies were eligible for inclusion regarding design, population, intervention, and comparator, but did not report outcomes of interest, they were not included for meta-analysis. However, we summarized reported outcomes for all included studies in the Characteristics of included studies table. • All-cause mortality up to 28 days. • Clinical status, assessed by need for respiratory support with standardized scales (e.g. WHO Clinical Progression Scale (Marshall 2020), herea er referred to as the WHO scale) up to 28 days. If the study did not use a standardized scale to assess the status of the participants, we categorized their status according to the WHO scale with the information provided by the study. Clinical status is a complex outcome with substantial heterogeneity. We pooled data only if clinically reasonable (see the list of specific outcomes below). When there were only a few studies available that reported di erent outcomes in terms of clinical status, we describe them in the results narratively. * Worsening of clinical status. □ Need for invasive mechanical ventilation (i.e. WHO scale 7 to 9, if 6 or less at baseline). □ Need for non-invasive mechanical ventilation or high flow (i.e. WHO scale 6, if 5 or less at baseline). □ Need for oxygen by mask or nasal prongs (i.e. WHO scale 5, if 4 or less at baseline). * Improvement of clinical status. □ Weaning or liberation from invasive mechanical ventilation in surviving participants (i.e. WHO scale 6 or less, if 7 or greater at baseline). □ Ventilator-free days (ventilator-free defined as WHO scale 6 or less). □ Duration of liberation from invasive mechanical ventilation. □ Liberation from supplemental oxygen in surviving participants (i.e. WHO scale 4 or less, if 5 or greater at baseline). □ Duration of liberation from supplemental oxygen. □ Participants discharged without respiratory deterioration or death at 28 days. • Adverse events (any grade, grade 1 to 2, grade 3 to 4), defined as number of participants with at least one event within 28 days. • All-cause mortality up to 28 days. • Clinical status, assessed by need for respiratory support with standardized scales (e.g. WHO scale (Marshall 2020)) up to 14 days. If the study did not use a standardized scale to assess the status of the participants, we categorized their status according to the WHO scale with the information provided by the study. Clinical status is a complex outcome with substantial heterogeneity. We pooled data only if clinically reasonable (see the list of specific outcomes below). When there were only a few studies available that reported di erent outcomes in terms of clinical status, we described the results narratively. * Development of moderate-to-severe clinical COVID-19 symptoms (defined as WHO scale 6 or greater). □ Need for invasive mechanical ventilation, non-invasive mechanical ventilation or high flow (i.e. WHO scale ≥ 6, severe disease). □ Need for invasive mechanical ventilation (i.e. WHO scale 7 to 9). □ Need for non-invasive mechanical ventilation or high flow (i.e. WHO scale 6). * Need for hospitalization with or without supplemental oxygen (i.e. WHO scale 4 to 5, moderate disease). □ Need for oxygen by mask or nasal prongs (i.e. WHO scale 5). □ Need for hospitalization without oxygen therapy (i.e. WHO scale 4). * Symptom resolution (i.e. WHO scale 1). □ Number of participants with symptoms resolved. □ Duration of symptom resolution. • Admission to hospital. • Adverse events (any grade, grade 1 to 2, grade 3 to 4), defined as number of participants with at least one event within 28 days. • SARS-CoV-2 infection (confirmed by RT-PCR or antigen testing) at 14 days. • Development of clinical assessed in accordance with individual items of the WHO scale (Marshall 2020). If the study did not use a standardized scale to assess the status of the participants, we categorized their status according to the WHO scale with the information provided by the study. * Uninfected (WHO scale 0). * Ambulatory mild disease (WHO scale 1 to 3). * Hospitalized with moderate disease (WHO scale 4 to 5). * Hospitalized with severe disease (WHO scale 7 to 9). * Mortality (WHO scale 10). • Adverse events (any grade, grade 1 to 2, grade 3 to 4), defined as number of participants with at least one event within 14 days. We expected that included studies measured several outcomesincluding clinical status, SARS-CoV-2 infection, and adverse events -at di erent time points. For inpatient setting outcomes, the main time point of interest was 28 days a er randomization. For outpatient setting outcomes, the main time point of interest was 14 days a er randomization, except for mortality and (serious) adverse events (28 days). For prevention trials, the main time point was 14 days, except for mortality only (28 days). If only a few studies had contributed data to an outcome, we pooled di erent time points, provided the studies had produced valid data and pooling was clinically reasonable. We reported time points of outcome measurement in the footnotes of the forest plots. If su icient data are available for review updates, we will group the measurement time points of eligible outcomes into those measured directly a er treatment (up to seven days), medium-term outcomes (up to 14 days), and longer-term outcomes (28 days or more). • Serious adverse events, defined as number of participants with at least one event within 28 days. • Quality of life assessed with the standardized scale, WHOQOL-100, up to 28 days (WHO 2012). • Admission to intensive care unit (ICU). • Duration of hospitalization. • Viral clearance, assessed with RT-PCR test for SARS-CoV-2 at baseline, and three, seven, and 14 days. • Serious adverse events, defined as number of participants with at least one event within 28 days. • Quality of life assessed with the standardized scale, WHOQOL-100, up to 14 days (WHO 2012) . • Viral clearance, assessed with RT-PCR test for SARS-CoV-2 at baseline, and at three, seven, and 14 days. • All-cause mortality up to 28 days. • Admission to hospital. • Quality of life assessed with the standardized scale, WHOQOL-100, up to 14 days (WHO 2012) . We expected that included studies measured several outcomesincluding serious adverse events, quality of life, and viral clearance -at di erent time points. We analyzed di erent time points for viral clearance separately due to the dynamic course of the viral load. For other inpatient setting outcomes, the main time point of interest was 28 days a er randomization. For other outpatient setting trials outcomes, the main time point of interest was 14 days a er randomization, except for mortality (28 days)and (serious) adverse events (28 days). For prevention trials, the main time point of interest was 14 days, except for mortality only (28 days). If only a few studies contributed data to an outcome, we pooled di erent time points, as long as the studies had produced valid data and pooling was clinically reasonable. We reported time points of outcome measurement in the footnotes of the forest plots. If su icient data are available for review updates, we will group the measurement time points of eligible outcomes into those measured directly a er treatment (up to seven days), medium-term outcomes (up to 14 days), and longer-term outcomes (28 days or more). On 26 May 2021, the Information Specialist (MIM) conducted systematic searches of the following sources with no restrictions on the language of publication. We did not conduct separate searches of the databases required by the Methodological Expectations of Cochrane Intervention Reviews (MECIR) standards (Higgins 2021), since these databases are already regularly searched for the production of the CCSR. For greater precision, we searched the Web of Science database from 1 January 2020 onwards. We searched all other resources without date limits. We searched the reference lists of included studies, systematic reviews, and meta-analyses to identify other potentially eligible studies or ancillary publications. We contacted the investigators of included studies to obtain additional information on the retrieved studies. We searched for grey literature, which we defined as searching trials registries such as ClinicalTrials.gov and WHO ICTRP contained in the CCSR, as well as searching preprint servers. In addition, we screened the 'All RCTs' section on the website ivmmeta.com, which lists studies related to ivermectin and COVID-19, and the regarding section on COVID-NMA Working Group for eligible trials. We performed study selection in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (Lefebvre 2020). Two review authors (SW, MP) independently screened titles and abstracts of identified records. We retrieved full-text articles and independently assessed eligibility of the remaining records against the predefined eligibility criteria. We resolved discrepancies through discussion between the review authors. We included studies irrespective of whether measured outcome data were reported in a 'usable' way. We collated multiple reports of the same study, so that the study, rather than the report, was the unit of interest in the review. We documented the study selection process in a PRISMA flow diagram with the total number of studies included, excluded, awaiting classification, and ongoing. We listed the reasons for exclusion and awaiting classification in the Characteristics of excluded studies and Characteristics of studies awaiting classification tables. Two review authors (SW, MP) independently extracted data using a standardized data extraction form, including details of the study, participants, intervention, comparator, and outcomes. If necessary, we tried to obtain missing data by contacting the authors of relevant articles. At each step of data extraction, we resolved any discrepancies through discussion between the review authors. We assessed the risk of bias in the included studies using the Cochrane risk of bias tool 2 (RoB 2) (Higgins 2020c; Sterne 2019). The e ect of interest was the e ect of assignment at baseline, regardless of whether the interventions were received as intended (the 'intention-to-treat e ect'). We assessed the risk of bias for all results (outcomes) reported in the included studies that we specified as outcomes for the current review and that contributed to the review's summary of findings table. Two review authors (SW, MP) independently assessed the risk of bias of all results. We resolved any disagreements through discussion with a third review author. The RoB 2 tool considers the following domains: • bias arising from the randomization process; • bias due to deviations from the intended interventions; • bias due to missing outcome data; • bias in measurement of the outcome; and • bias in selection of the reported result. We assessed the RoB 2 domains using the recommended signalling questions and these response options: • yes; • probably yes; • probably no; RoB 2 algorithms map responses to signalling questions. We used the proposed algorithm a er verification to reach a risk of bias judgement, and assigned one of three levels to each domain: • low risk of bias; • some concerns; or • high risk of bias. Similarly, we reached an overall risk of bias judgement for a specific outcome by considering all domains resulting in one of the three judgement options described above. Overall low risk of bias of the trial result was assumed when all domains were at low risk; some concerns of bias was assumed when the trial result was judged to raise some concerns in at least one domain for this result, but not at high risk of bias for any domain; overall high risk of bias of the trial result was assumed when the trial was at high risk of bias in at least one domain for this result or when it was judged to have some concerns for multiple domains in a way that substantially lowered confidence in the result (Higgins 2020c). We used the RoB 2 Excel tool to implement RoB 2 (available at www.riskofbias.info/welcome/rob-2-0-tool/current-version-ofrob-2). We stored the full RoB 2 data (e.g. completed Excel tool) in an online repository. The primary analysis included only those studies that had low risk or some concerns of bias. We included studies at high risk of bias in a secondary analysis to assess the impact on the results. For dichotomous outcomes, we recorded the number of events and the number of analyzed participants in the intervention and control groups. We used the risk ratio (RR) with 95% confidence interval (CI) as e ect measure. For continuous outcomes, we recorded the mean, the standard deviation (SD), and the number of analyzed participants in the intervention and control groups. If the standard deviation was not reported, we used standard errors, CIs, or P values to calculate the SD with the formulas described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2020d). If studies reported data as median with interquartile range (IQR), we assumed that the median was similar to the mean when sample sizes were large and the distribution of the outcome was similar to the normal distribution. In these cases, the width of the IQR is approximately 1.35 SDs (Higgins 2020d). We used the MD with 95% CI as e ect measure. We considered e ect estimates of dichotomous outcomes with the range of the 95% CIs not crossing 1 and continuous outcomes with the range of the 95% CIs not crossing 0 as statistically significant e ect estimates. A statistically significant e ect does not necessarily mean that the estimated e ect is clinically relevant. We assessed the clinical relevance of the e ect size separately and reported it transparently. The unit of analysis for this review was the individually randomized participant. In studies with multiple intervention groups, we combined groups if reasonable (e.g. study arms with di erent doses of ivermectin). If it had not been reasonable to pool the groups, we planned to split the 'shared' comparator group to avoid double-counting of participants. There was no need to split shared groups for the current review. There are many potential sources of missing data in a systematic review or meta-analysis, which can a ect the level of studies, outcomes, summary data, individuals, or study-level characteristics (Deeks 2020). Incomplete data can introduce bias into the meta-analysis, if they are not missing at random. We addressed all sources of missing data. Missing studies may be the result of reporting bias, and we addressed this as described in the Assessment of reporting biases section. Missing outcomes and summary data may be the result of selective reporting bias; missing individuals may be the result of attrition from the study or lack of intention-to-treat analysis. We addressed these sources of missing data using the RoB 2 tool (Assessment of risk of bias in included studies). If data were incompletely reported, we contacted the study authors to request additional information. We used the descriptive statistics reported in the Characteristics of included studies table to assess whether the studies within each pairwise comparison were homogeneous enough, with respect to study and intervention details and population baseline characteristics, that the assumption of homogeneity might be plausible. In case of excessive clinical heterogeneity, we did not pool the findings of included studies. We measured statistical heterogeneity using the Chi 2 test and the I 2 statistic (Deeks 2020), and the 95% prediction interval (PI) for random-e ects meta-analysis (IntHout 2016). The prediction interval helps in the clinical interpretation of heterogeneity by estimating what true treatment e ects can be expected in future settings (IntHout 2016). We restricted calculation of a 95% PI to meta-analyses with four or more studies (200 participants or more), since the interval would be imprecise when a summary estimate was based on only a few small studies. In the current review, there are no meta-analyses including four or more studies. We planned to use the open-source statistical so ware R package meta to calculate 95% PIs in review updates (Meta). We declared statistical heterogeneity if the P value was less than 0.1 for the Chi 2 statistic, or the I 2 statistic was equal to or greater than 40% (40% to 60%: moderate heterogeneity; 50% to 90%: substantial heterogeneity; 75% to 100%: considerable heterogeneity; Deeks 2020), or the range of the 95% PI revealed a di erent clinical interpretation of the e ect estimate compared to the 95% CI. We sought to identify all research that met our predefined eligibility criteria. Missing studies can introduce bias to the analysis. We searched for completed non-published trials in trials registers, contacted authors to seek assurance that the results will be made available, and classified them as 'awaiting classification' until the results are reported. We reported the number of completed nonpublished trials. Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews When there are 10 or more relevant studies pooled in a meta-analysis, we planned to investigate risk of reporting bias (publication bias) in pairwise meta-analyses using contourenhanced funnel plots. In the current review, there were no metaanalyses including 10 or more studies. For review updates, if funnel plot asymmetry is suggested by a visual assessment, we plan to perform exploratory analyses (e.g. Rücker's arcsine test for dichotomous data and Egger's linear regression test for continuous data) to further investigate funnel plot asymmetry. A P value of less than 0.1 will be considered as the level of statistical significance. In review updates, we will analyse reporting bias using the opensource statistical so ware R package meta (Meta). The primary analysis included only those studies that had low risk or some concerns of bias according to the RoB 2 assessment. We included high risk of bias studies in a secondary analysis to assess the impact on the results (Sensitivity analysis). We analyzed trials with di erent intentions of ivermectin use and di erent participant populations separately, as follows. • Treatment of COVID-19 in an inpatient setting: participants with confirmed SARS-CoV-2 infection. • Treatment of COVID-19 in an outpatient setting: participants with confirmed SARS-CoV-2 infection. • Prevention of SARS-CoV-2 infection (postexposure prophylaxis): participants at high risk of developing the infection. We created these comparisons. • Ivermectin versus placebo or standard of care. • Ivermectin versus active pharmacological intervention with proven e icacy. We performed meta-analyses according to the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions (Deeks 2020). If clinical and methodological characteristics of individual studies were su iciently homogeneous, we pooled the data in metaanalyses. When meta-analysis was feasible, we used the randome ects model as we assumed that the intervention e ects were related but were not the same for the included studies. For dichotomous outcomes, we performed meta-analyses using the Mantel-Haenszel method under a random-e ects model to calculate the summary (combined) intervention e ect estimate as a weighted mean of the intervention e ects estimated in the individual studies. For continuous outcomes, we used the inversevariance method. We used RevMan Web so ware for meta-analyses (RevMan Web 2020). For ivermectin used as treatment for COVID-19 in an inpatient setting, we planned to perform a subgroup analysis independent of heterogeneity for the following characteristic. • Severity of condition at baseline (moderate (WHO scale 4 to 5) versus severe disease (WHO scale 6 to 9)). Since only one study investigated participants with moderate-tosevere COVID-19, the planned subgroup analysis for severity at baseline could not be performed. For ivermectin used to prevent SARS-CoV-2 infection, we planned to perform a subgroup analysis independent of heterogeneity for the following characteristic. • Studies including participants with a history of SARS-CoV-2 infection versus studies including only participants with no history of infection. We investigated heterogeneity by visual inspection of the forest plot. We reported details of the intervention and age of the population for each study in the footnotes of the forest plot. We planned to investigate heterogeneity by subgroup analysis to calculate RR or MD in conjunction with the corresponding CI for each subgroup, if su icient studies had been available (at least 10 studies per outcome). In the current review, there were not enough studies available. In review updates, we will perform subgroup analyses if statistical heterogeneity is present (P < 0.1 for the Chi 2 test of heterogeneity, I 2 of 50% or greater, or a di erent clinical conclusion of 95% CI versus 95% PI). In review updates, we will perform subgroup analyses to investigate heterogeneity for the following characteristics. • Ivermectin used as treatment (inpatients and outpatients): * dose of ivermectin (low versus high); * age (children versus adults). • Ivermectin used for prevention: * dose of ivermectin (low versus high); * mode of exposure (e.g. working place, nursing home) and burden of exposure (e.g. living in a high-risk area, high-risk medical contact) in prevention studies; * confirmation of SARS-CoV-2 infection (RT-PCR versus antigen testing; for the outcome 'SARS-CoV-2 infection'). We used sensitivity analyses to test the robustness of the metaanalyses. We excluded: • non-peer reviewed studies (including preprint articles); • studies reporting data as median instead of mean for continuous outcomes; in the current review version there were no data reported as median that were eligible for a transformation into mean. Since high risk of bias trials were excluded from the primary analysis, we performed a secondary analysis including the studies judged as overall high risk of bias to assess the impact of those studies on the results. We presented the main results of the review in summary of findings tables, including a rating of the certainty of evidence based on the GRADE approach. We followed current GRADE guidance as recommended in the Cochrane Handbook for Systematic Reviews of Interventions (Schünemann 2020). Trusted evidence. Informed decisions. Better health. Two review authors (SW, MP) assessed the certainty of evidence, considering risk of bias, inconsistency, imprecision, indirectness, and publication bias. We used the overall RoB 2 assessment to inform the risk of bias judgement underlying the assessment of the certainty of evidence. The primary analysis including only studies at overall low risk or some concerns of bias were used as data basis for the summary of findings tables. We created separate summary of findings tables for the use of ivermectin with di erent intentions (e.g. treatment of people with COVID-19 in inpatient and outpatient settings, and prevention of SARS-CoV-2 infection) and for di erent comparisons with regard to the intervention and comparator. For the current review, we found no studies with active comparators. The summary of findings tables included the following outcomes (primary analysis). For use of ivermectin with intention to treat COVID-19 in an inpatient setting: • all-cause mortality up to 28 days; • clinical worsening or improvement of symptoms up to 28 days, assessed as need for respiratory support; • adverse events (any grade) up to 28 days; • quality of life up to 28 days; • duration of hospitalization; • viral clearance at seven days. For use of ivermectin with intention to treat COVID-19 in an outpatient setting: • all-cause mortality up to 28 days; • clinical worsening or improvement of symptoms up to 14 days, assessed as need for respiratory support; • admission to hospital; • adverse events (any grade) up to 28 days; • quality of life up to 14 days; • viral clearance at 7 days. For use of ivermectin with intention to prevent SARS-CoV-2 infection: • SARS-CoV-2 infection (confirmed by RT-PCR or antigen testing) at 14 days; • development of clinical COVID-19 symptoms up to 14 days; assessed in accordance with the WHO scale; • adverse events (any grade) up to 14 days; • all-cause mortality up to 28 days; • admission to hospital at day 14; • quality of life up to 14 days. The GRADE assessment resulted in one of four levels of certainty and these express our confidence in the estimate of e ect (Balshem 2011). • High certainty: we are very confident that the true e ect lies close to that of the estimate of the e ect. • Moderate certainty: we are moderately confident in the e ect estimate; the true e ect is likely to be close to the estimate of the e ect, but there is a possibility that it is substantially di erent. • Low certainty: our confidence in the e ect estimate is limited; the true e ect may be substantially di erent from the estimate of the e ect. • Very low certainty: we have very little confidence in the e ect estimate; the true e ect is likely to be substantially di erent from the estimate of e ect. We used the MAGICapp to create summary of findings tables (MAGICapp), and incorporated the results into RevMan Web manually (RevMan Web 2020). Living systematic review considerations Our information specialist (MIM) will provide us with new search records each week, which two review authors will screen, extract, evaluate, and integrate following the guidance for Cochrane living systematic reviews (Cochrane LSR). We will manually check platform trials for new treatment arms investigating ivermectin. We will wait until the accumulating evidence changes our conclusions of the implications of research and practice before republishing the review. We will consider one or more of the following components to inform this decision. • The findings of one or more prioritized outcomes. • The credibility (e.g. GRADE rating) of one or more prioritized outcomes. • New settings, populations, interventions, comparisons, or outcomes studied. In case of emerging policy relevance because of global controversies around the intervention, we will consider republishing an updated review even though our conclusions remain unchanged. We will review the review scope and methods approximately monthly, or more frequently if appropriate, in light of potential changes in COVID-19 research (e.g. when additional comparisons, interventions, subgroups, or outcomes, or new review methods become available). Cochrane Database of Systematic Reviews The overall population mean age of the included studies was 43 years. Chaccour 2021 included the youngest participants with a population median age of 28 years. Okumuş 2021 included the oldest participants with a population mean age of 62 years. The mean proportion of men in all included studies was 59%. The lowest proportions of men were included in Chachar 2020 and López-Medina 2021 with 42% men, while Shah Bukhari 2021 included the highest proportion with 85% men. The studies partially reported comorbidities and relevant risk factors such as obesity, diabetes, respiratory diseases, hypertension, and immunosuppression (see Characteristics of included studies table). Two studies excluded existing comorbidities and specified them in the inclusion and exclusion criteria (Chaccour 2021; Krolewiecki 2020). Four studies reported no data on risk factors in their publications or study reports (Ahmed 2020; Kishoria 2020; Podder 2020; Pott-Junior 2021). All studies administered ivermectin orally. The only prevention study compared ivermectin to no treatment (Shoumann 2021). One study did not report outcomes eligible for meta-analysis due to a short follow-up period of seven days (Chachar 2020). In trials with intention to treat COVID-19, the most investigated primary outcomes as defined by the study were either (time to) viral clearance or a reduction in the viral load reported in eight studies (Ahmed 2020; Chaccour 2021; Kirti 2021; Kishoria 2020; Krolewiecki 2020; Mohan 2021; Pott-Junior 2021; Shah Bukhari 2021). Chachar 2020 and López-Medina 2021 defined resolution of symptoms as primary outcomes, and Ahmed 2020 defined remission of fever and cough as an additional primary outcome. The primary outcomes in Gonzalez 2021 were duration of hospitalization until discharge due to clinical improvement and duration of hospitalization. The primary outcome in Okumuş 2021 was clinical response. Two studies defined safety outcomes as additional primary outcomes (Gonzalez 2021; Okumuş 2021). Podder 2020 did not define any primary outcome. In the only prevention trial, the primary outcome was development of COVID-19 typical symptoms (Shoumann 2021). Three studies had already been published or had results posted in the trial registry (Faisal 2020; NCT04407507; Samaha 2021). However, despite using the term 'randomized controlled trial,' there were contradictory details throughout the published text or protocol that led us to believe those studies were not fulfilling criteria of genuine RCTs. We contacted study authors for clarification but received no response at the time of review publication. We identified five completed and potentially eligible RCTs from trial register entries, but there were no results available or published ( Cochrane Database of Systematic Reviews (NCT04894721), another one including 2000 close contacts will be completed in October 2021 (PACTR202102848675636). Finally, one study is evaluating postexposure prophylaxis in 550 healthcare workers (NCT04527211). This study was supposed to be completed in December 2020, but according to the trial registry has not started recruiting yet. We found no studies comparing ivermectin to an active comparator eligible for this review. We assessed methodological quality and risk of bias for 13 RCTs contributing results to our prioritized outcomes using the RoB 2 tool ( Most of the 41 study results (56.1%) had some concerns for the overall risk of bias. Thirteen (31.7%) of the 41 study results were at overall high risk of bias. We excluded studies with overall high risk of bias from the primary meta-analyses of the review. The main reasons a study result was assessed at high risk of bias were missing outcome data and measurement of the outcome. Studies with high risk of bias were included in secondary meta-analyses. Two studies contributing five study results (12.2%) to four outcomes, including all-cause mortality, adverse events, and viral clearance at three and seven days, were at overall low risk of bias (Chaccour 2021; Mohan 2021). The following section summarizes the risk of bias per outcome (primary analysis) for all outcomes included in the summary of findings tables (Summary of findings 1; Summary of findings 2; Summary of findings 3). Two studies contributed results to the primary analysis of mortality up to 28 days and risk of bias was assessed as some concerns. Gonzalez 2021 provided insu icient information on allocation concealment and blinding of healthcare providers, and did not define the time point of outcome measurement in the protocol. Kirti 2021 performed an inappropriate analysis (perprotocol analysis). Two studies contributed results to the primary analysis of need for invasive mechanical ventilation up to 28 days and risk of bias was assessed as some concerns. Gonzalez 2021 provided insu icient information on allocation concealment and blinding of healthcare providers, and did not define the time point of outcome measurement in the protocol. Kirti 2021 performed an inappropriate analysis (per-protocol analysis). One study contributed results to the primary analysis of need for oxygen by mask or nasal prongs up to 28 days and risk of bias was assessed as some concerns. Ahmed 2020 provided insu icient information on randomization, allocation concealment, and blinding of participants and healthcare providers, and did not provide a prospectively registered protocol. Participants discharged without respiratory deterioration or death at 28 days One study contributed results to the primary analysis of patients discharged without respiratory deterioration or death at 28 days and risk of bias was assessed as some concerns. Gonzalez 2021 provided insu icient information on allocation concealment and blinding of healthcare providers and did not register the outcome in the protocol. One study contributed results to the primary analysis of any adverse events within 28 days and risk of bias was assessed as some concerns. Mohan 2021 provided insu icient information on definition and measurement of the outcome, and did not prespecify the outcome in the prospectively registered protocol. Three studies with high risk of bias were not eligible for the primary analysis (Krolewiecki 2020; Pott-Junior 2021; Shah Bukhari 2021). All three studies provided insu icient information on definition, and measurement of the outcome and outcome assessors were not blinded. One study had missing outcome data of more than 14% (Shah Bukhari 2021). Participants withdrew against medical advice before completion of the study. One study contributed results to the primary analysis of duration of hospitalization and risk of bias was assessed as some concerns. Ahmed 2020 provided insu icient information on randomization, allocation concealment, and blinding of participants and healthcare providers, and did not provide a prospectively registered protocol. Two studies contributed results to the primary analysis of viral clearance at seven days and risk of bias was assessed as some concerns. Mohan 2021 was at overall low risk of bias. Ahmed 2020 provided insu icient information on randomization, allocation concealment, blinding of participants and healthcare providers, and did not provide a prospectively registered protocol. Two studies with high risk of bias were not eligible for the primary analysis (Kirti 2021; Pott-Junior 2021). Kirti 2021 had more than 30% of missing data due to discharge or inconclusive results. In Pott-Junior 2021, participants and those delivering the intervention were aware of the intervention received and 25% of participants Cochrane Database of Systematic Reviews (one of four) in the control group were excluded due to protocol violations (per-protocol analysis). Protocol violations were not described. All-cause mortality up to 28 days Two studies contributed results to the primary analysis of mortality up to 28 days and risk of bias was assessed as some concerns. Chaccour 2021 was at overall low risk of bias. In López-Medina 2021, the primary analysis was per-protocol due to a labelling error that resulted in 16% of participants receiving the wrong intervention. Both participants and those delivering the intervention were unaware of intervention received and reported an as-treated sensitivity analysis where results did not di er. One study contributed results to the primary analysis of need for invasive mechanical ventilation at 14 days and risk of bias was assessed as some concerns. In López-Medina 2021, the primary analysis was per-protocol due to a labelling error that resulted in 16% of participants receiving the wrong intervention. Both participants and those delivering the intervention were unaware of intervention received and reported an as-treated sensitivity analysis where results did not di er. One study contributed results to the primary analysis of need for non-invasive mechanical ventilation or high flow up to 14 days and risk of bias was assessed as some concerns. In López-Medina 2021, the primary analysis was per-protocol due to a labelling error that resulted in 16% of participants receiving the wrong intervention. Both participants and those delivering the intervention were unaware of intervention received and reported an as-treated sensitivity analysis where results did not di er. One study contributed results to the primary analysis of number of participants with symptoms resolved up to 14 days and risk of bias was assessed as some concerns. In López-Medina 2021, the primary analysis was per-protocol due to a labelling error that resulted in 16% of participants receiving the wrong intervention. Both participants and those delivering the intervention were unaware of intervention received and reported an as-treated sensitivity analysis where results did not di er. No study reporting duration of symptom resolution was eligible for primary analysis. One study reported data as median with interquartile range, which were not eligible for meta-analysis (López-Medina 2021). The other study was not eligible for a primary analysis because of an overall high risk of bias assessment due to inadequate randomization and lack of blinding of participants, healthcare providers, and outcome assessors, and due to missing outcome data and lack of a registered protocol (Podder 2020). Two studies contributed results to the primary analysis of any adverse events within 28 days and risk of bias was assessed as some concerns. Chaccour 2021 was at overall low risk of bias. In López-Medina 2021, the primary analysis was per-protocol due to a labelling error that resulted in 16% of participants receiving the wrong intervention. Both participants and those delivering the intervention were unaware of intervention received and reported an as-treated sensitivity analysis where results did not di er. One study contributed results to the primary analysis of viral clearance at seven days and risk of bias was assessed as low. Chaccour 2021 was at low risk of bias in all domains. No study reporting development of clinical COVID-19 symptoms up to 14 days was eligible for primary analysis. One study reported results that were not eligible for the primary analysis because of an overall high risk of bias assessment due to lack of information on measurement of the outcome and lack of blinding of outcome assessors (Shoumann 2021). No study reporting any adverse events within 14 days was eligible for primary analysis. One study reported results that were not eligible for the primary analysis because of an overall high risk of bias assessment due to lack of information on measurement of the outcome and lack of blinding of outcome assessors (Shoumann 2021). One study contributed results to the primary analysis of mortality up to 28 days and risk of bias was assessed as some concerns. Shoumann 2021 provided insu icient information on randomization, allocation concealment, and missing outcome data, and did not prospectively register the outcome. One study investigated ivermectin compared to no treatment for preventing SARS-CoV-2 infection and contributed data to metaanalyses (Shoumann 2021). The main findings are summarized in Summary of findings 3. Two studies comparing ivermectin to placebo reported data on mortality at 28 days for 185 participants with moderate disease (Gonzalez 2021; Kirti 2021). Both studies were included in the primary meta-analysis due to the overall risk of bias assessment (Analysis 1.1). In the meta-analysis, five participants died in the ivermectin group and nine participants in the placebo group. We are uncertain whether ivermectin reduces or increases all-cause mortality up to 28 days compared to placebo (RR 0.60, 95% CI 0.14 to 2.51; 2 RCTs, 185 participants; very low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias and two levels for very serious imprecision due to few participants, few events, and wide CIs. Both studies were published as preprint articles. Two studies in an inpatient setting reported mortality at time points not eligible for meta-analysis. Mohan 2021 reported mortality at 14 days, which is too short, and Okumuş 2021 reported an unclear time frame of follow-up. In both cases, data were not comparable with studies reporting our predefined time point of 28 days. Two studies comparing ivermectin to placebo reported data on clinical worsening assessed by need for invasive mechanical ventilation at 28 days for 185 participants with moderate disease (Gonzalez 2021; Kirti 2021). Both studies were included in the primary meta-analysis due to the overall risk of bias assessment (Analysis 1.2). In the meta-analysis, four participants in the ivermectin group and eight participants in the placebo group showed clinical worsening. We are uncertain whether ivermectin reduces or increases clinical worsening assessed by the need for invasive mechanical ventilation compared to placebo up to 28 days (RR 0.55, 95% CI 0.11 to 2.59; 2 studies, 185 participants; very low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias and two levels for very serious imprecision due to few participants, few events, and wide CIs. Both studies were published as preprint articles. Two studies in an inpatient setting reported worsening of clinical status at seven days (Krolewiecki 2020) and 14 days (Mohan 2021), which was clinically not comparable with studies reporting our predefined time point of 28 days. Therefore, those studies were not eligible for meta-analysis. No study reported data for need for non-invasive mechanical ventilation or high flow up to 28 days. One study comparing ivermectin to placebo assessed need for oxygen by mask or nasal prongs during the study period (14 days) for 45 participants without supplemental oxygen at baseline, but none of the participants in either group required supplemental oxygen during the study (Ahmed 2020). We accepted the shorter time point of 14 days for the outcome as there are no other data available that would cause clinical incompatibility. The study was included in the primary meta-analysis due to the overall risk of bias assessment (Analysis 1.3). We are uncertain whether ivermectin reduces or increases clinical worsening assessed by the need for oxygen support up to 28 days compared to placebo (RR not estimable; 1 study, 45 participants; very low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias and two levels for very serious imprecision due to zero events and few participants. Ahmed 2020 was published as a journal article. No study reported data for weaning or liberation from invasive mechanical ventilation in surviving participants up to 28 days. No study reported data for ventilator-free days. No study reported data for duration of liberation from invasive mechanical ventilation. No study reported data for liberation from supplemental oxygen in surviving participants up to 28 days. No study reported data for duration of liberation from supplemental oxygen. Trusted evidence. Informed decisions. Better health. Participants discharged without respiratory deterioration or death at 28 days One study comparing ivermectin to placebo in 73 participants with moderate disease reported patients discharged without respiratory deterioration or death at 28 days (Gonzalez 2021). The study was included in the primary meta-analysis due to the overall risk of bias assessment (Analysis 1.4). In both groups, 27 participants were discharged without respiratory deterioration or death at 28 days. Ivermectin may have little or no e ect on clinical improvement assessed by the number of participants discharged without respiratory deterioration or death up to 28 days compared to placebo (RR 1.03, 95% CI 0.78 to 1.35; 1 study, 73 participants; low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias and one level for serious imprecision due to few participants. Gonzalez 2021 was published as a preprint article. Four studies comparing ivermectin to placebo or standard of care reported any adverse events within 14 days (Mohan 2021), 28 days (Pott-Junior 2021; Shah Bukhari 2021), and one month (Krolewiecki 2020) in 314 participants with moderate disease. One of these studies was included in the primary analysis due the overall risk of bias assessment (Analysis 1.5) (Mohan 2021). We are uncertain whether ivermectin may increase or reduce any adverse events up to 28 days compared to placebo (RR 1.21, 95% CI 0.50 to 2.97; 1 study, 152 participants; very low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias and two levels for very serious imprecision due to few participants and wide CIs. The other three studies with high risk of bias were included in a secondary analysis (Analysis 1.6) (Krolewiecki 2020; Pott-Junior 2021; Shah Bukhari 2021). The e ect estimate of the secondary analysis was comparable to the primary analysis (RR 1.04, 95% CI 0.61 to 1.79; 4 studies, 314 participants). Only the study included in the primary analysis was published as a preprint article (Mohan 2021). Okumuş 2021 reported adverse events within five days and was not eligible for meta-analysis on adverse events within 28 days due to the short follow-up period. Three studies comparing ivermectin to placebo or standard of care reported serious adverse events within 14 days (Ahmed 2020; Mohan 2021) and 30 days (Krolewiecki 2020) in 242 participants with moderate disease. Two of these studies with 197 participants were included in the primary analysis due the overall risk of bias assessment (Analysis 1.7) (Krolewiecki 2020; Mohan 2021). We are uncertain whether ivermectin increases or reduces serious adverse events up to 28 days compared to placebo or standard of care (RR 1.55, 95% CI 0.07 to 35.89; 2 studies, 197 participants). The other study with high risk of bias was included in a secondary analysis (Analysis 1.8) (Ahmed 2020). The e ect estimate of the secondary analysis is identical to the primary analysis as the study contributed no events (RR 1.55, 95% CI 0.07 to 35.89; 3 studies, 242 participants). The two studies included in the primary analysis were published as preprint articles (Krolewiecki 2020; Mohan 2021). No study reported data for quality of life up to 28 days. Two studies comparing ivermectin to placebo or standard of care reported the number of participants who were admitted to ICU at 28 days for participants with moderate disease (Kirti 2021; Pott-Junior 2021). Both studies with 143 participants were included in the primary analysis due the overall risk of bias assessment (Analysis 1.9). We are uncertain whether ivermectin increases or reduces the number of participants who were admitted to the ICU at 28 days compared to placebo or standard of care (RR 0.53, 95% CI 0.11 to 2.51; 2 studies, 143 participants). One study was published as a preprint article (Kirti 2021), the other was published as journal publication (Pott-Junior 2021). The sensitivity analysis including only the study published in a journal estimated the intervention e ect at RR 0.15 (95% CI 0.01 to 1.93; 1 study, 31 participants). Two studies comparing ivermectin to placebo reported duration of hospitalization (Ahmed 2020; Gonzalez 2021). One of these studies reported data as median with IQR on duration of hospitalization in 73 participants with moderate disease (Gonzalez 2021). The median duration of hospitalization in the ivermectin group was six days (IQR 4 to 11 days) compared to five days (IQR 4 to 7 days) in the placebo group. Ahmed 2020, investigating 45 participants with moderate disease, was included in the primary meta-analysis due to the overall risk of bias assessment and reporting data as means with SDs (Analysis 1.10). Ivermectin may have little or no e ect on duration of hospitalization compared to placebo (MD −0.10 days, 95% CI −2.43 to 2.23; 1 study, 45 participants; low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias and one level for serious imprecision due to few participants. Ahmed 2020 was published as a journal article and Gonzalez 2021 was published as a preprint article. Four studies comparing ivermectin to placebo or standard of care reported viral clearance at three days in 288 participants with moderate disease (Ahmed 2020; Kishoria 2020; Mohan 2021; Shah Bukhari 2021). Two of the studies with 170 participants were included in the primary analysis due to the overall risk of bias assessment (Analysis 1.11) (Ahmed 2020; Mohan 2021). We are uncertain whether ivermectin increases or reduces viral clearance at three days compared to placebo (RR 1.02, 95% CI 0.45 to 2.32; 2 studies, 170 participants). The other two studies with high risk of bias were included in a secondary analysis (Analysis 1.12) (Kishoria 2020; Shah Bukhari 2021). The point estimate of the secondary analysis favoured ivermectin, but the 95% CI was wide including 1 and heterogeneity was high (RR 1.73, 95% CI 0.59 to 5.04; I 2 = 73%; 4 studies, 288 participants). One study included in the primary analysis was published as a preprint article (Mohan 2021), the other study was published as a journal article (Ahmed 2020). The sensitivity analysis including only the study published in a journal estimated the intervention e ect at RR 2.09 (95% CI 0.42 to 10.29; 1 study, 45 participants). Four studies comparing ivermectin to placebo or standard of care reported viral clearance at seven days in 265 participants with moderate disease (Ahmed 2020; Kirti 2021; Mohan 2021; Pott-Junior 2021). Two of the studies with 159 participants were included in the primary analysis due the overall risk of bias Cochrane Database of Systematic Reviews assessment (Analysis 1.13) (Ahmed 2020; Mohan 2021). We are uncertain whether ivermectin increases or reduces viral clearance at seven days compared to placebo (RR 1.82, 95% CI 0.51 to 6.48; 2 studies, 159 participants; very low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias, one level for serious heterogeneity (I 2 = 77%), and two levels for very serious imprecision due to few participants and wide CIs. The other two studies with high risk of bias were included in a secondary analysis (Analysis 1.14) (Kirti 2021; Pott-Junior 2021). The point estimate of the secondary analysis lay closer to 1 and the 95% CI was wide and included 1 (RR 1.19, 95% CI 0.76 to 1.86; 4 studies, 265 participants). One study included in the primary analysis was published as a preprint article (Mohan 2021), the other study was published as a journal article (Ahmed 2020). The sensitivity analysis including only the study published in a journal favoured ivermectin compared to placebo (RR 3.83, 95% CI 1.23 to 11.93; 1 study, 45 participants). Two studies comparing ivermectin to placebo or standard of care reported viral clearance at 14 days in 69 participants with moderate-to-severe disease (Ahmed 2020; Okumuş 2021). One of the studies with 45 participants was included in the primary analysis due the overall risk of bias assessment (Analysis 1.15) (Ahmed 2020). Ivermectin may increase viral clearance at 14 days compared to placebo (RR 1.97, 95% CI 1.13 to 3.45; 1 study, 45 participants). The other study with high risk of bias was included in a secondary analysis (Analysis 1.16) (Okumuş 2021). The e ect estimate of the secondary analysis was comparable to the primary analysis (RR 2.07, 95% CI 1.28 to 3.33; 2 studies, 69 participants). The study included in the primary analysis was published as a journal article (Ahmed 2020). Two studies comparing ivermectin to placebo reported data on mortality at 21 days (López-Medina 2021) and at 28 days (Chaccour 2021) for 422 participants with mild disease. Both studies were included in the primary meta-analysis due to the overall risk of bias assessment (Analysis 2.1). In the meta-analysis, none of the participants died in the ivermectin group and one participant died in the placebo group. We are uncertain whether ivermectin reduces or increases all-cause mortality up to 28 days compared to placebo (RR 0.33, 95% CI 0.01 to 8.05; 2 studies, 422 participants; very low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias and two levels for very serious imprecision due to few participants, few events, and wide CIs. Both studies were published as journal articles. Need for invasive mechanical ventilation, or non-invasive mechanical ventilation or high flow One study comparing ivermectin to placebo reported data on clinical worsening assessed by need for invasive mechanical ventilation at 15 days in 398 participants with mild disease (López-Medina 2021). The study was eligible for the primary meta-analysis due to the overall risk of bias assessment (Analysis 2.2). One participant in the ivermectin group and no participants in the placebo group showed clinical worsening. We are uncertain whether ivermectin reduces or increases clinical worsening assessed by the need for invasive mechanical ventilation compared to placebo up to 14 days (RR 2.97, 95% CI 0.12 to 72.47; 1 study, 398 participants; very low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias and two levels for very serious imprecision due to few participants, few events, and wide CIs. The study was published as a journal article. One study comparing ivermectin to placebo reported the need for non-invasive mechanical ventilation or high flow at 15 days in 398 participants with mild disease (López-Medina 2021). None of the participants in either group required non-invasive mechanical ventilation or high flow at 15 days. The study was eligible for the primary analysis due to the overall risk of bias assessment (Analysis 2.3). We are uncertain whether ivermectin reduces or increases clinical worsening assessed by the need for non-invasive mechanical ventilation or high flow at 15 days compared to placebo (RR not estimable; 1 study, 398 participants; very low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias and two levels for very serious imprecision due to zero events and few participants. López-Medina 2021 was published as a journal article. López-Medina 2021 reported hospitalization with or without supplemental oxygen. The data were not eligible for meta-analysis as less than 1% of the participants already had a WHO status of 4 and 5 at baseline. Therefore, these data were not useful to judge clinical worsening. No study reported data for need for oxygen by mask or nasal prongs up to 14 days. No study reported data for need for hospitalization without oxygen therapy up to 14 days. One study comparing ivermectin to placebo reported data on symptom resolution at 15 days in 398 participants with mild disease (López-Medina 2021). The study was eligible for the primary metaanalysis due to the overall risk of bias assessment (Analysis 2.4). Ivermectin may have little or no e ect on clinical improvement assessed by the number of participants with symptoms resolved up to 14 days (RR 1.04, 95% CI 0.89 to 1.21; 1 study, 398 participants; low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias and one level for serious imprecision due to few participants. The study was published as a journal article. Chachar 2020 reported symptom resolution within seven days, which was too early and clinically not comparable to our predefined time point of 14 days. Trusted evidence. Informed decisions. Better health. Two studies reported data on duration of symptom resolution (López-Medina 2021; Podder 2020). One studies comparing ivermectin to placebo reported data as median with IQR on duration of symptom resolution in 398 participants with mild disease (López-Medina 2021). The median duration of symptom resolution in the ivermectin group was 10 days (IQR 9 to 13 days) compared to 12 days (IQR 9 to 13 days) in the placebo group. The study was not eligible for meta-analysis due to an asymmetric distribution of the data. The other study comparing ivermectin to standard of care reported data as means with SDs on duration to symptom resolution in 62 participants with mild disease (Podder 2020). The study was not eligible for a primary analysis due to the overall risk of bias assessment. This study with high risk of bias was analyzed in a secondary analysis (Analysis 2.5). The e ect estimate of the secondary analysis showed no clinically relevant di erence in the duration to symptom resolution (MD −1.02 days, 95% CI −2.76 to 0.72; 1 study, 62 participants). Both studies were published as journal articles. No study reported data for admission to hospital. Two studies comparing ivermectin to placebo reported any adverse events within 21 days (López-Medina 2021) and 28 days (Chaccour 2021) in 422 participants with mild disease. Both studies were included in the primary analysis due the overall risk of bias assessment (Analysis 2.6). Ivermectin may have little or no e ect on any adverse events compared to placebo (RR 0.95, 95% CI 0.86 to 1.05; 2 studies, 422 participants; low-certainty evidence). We downgraded the certainty of evidence one level for serious risk of bias and one level for serious imprecision due to few participants. Both studies were published as journal articles. Chachar 2020 reported adverse events within seven days, which was not eligible for meta-analysis due to the short follow-up period. Two studies comparing ivermectin to placebo reported serious adverse events within 21 days (López-Medina 2021) and 28 days (Chaccour 2021) in 422 participants with mild disease. Both studies were included in the primary analysis due the overall risk of bias assessment (Analysis 2.7). Chaccour 2021 reported zero events in both groups. We are uncertain whether ivermectin increases or reduce serious adverse events within 28 days compared to placebo (RR 0.99, 95% CI 0.14 to 6.96; 2 studies, 422 participants). Both studies were published as journal articles. No study reported data for quality of life up to 14 days. No study reported data for viral clearance at three days. One study comparing ivermectin to placebo reported viral clearance at seven days in 24 participants with mild disease (Chaccour 2021). The study was eligible for the primary analysis due the overall risk of bias assessment (Analysis 2.8). We are uncertain whether ivermectin increases or reduces viral clearance at seven days compared to placebo (RR 3.00, 95% CI 0.13 to 67.06; 1 study, 24 participants; low-certainty evidence). We downgraded the certainty of evidence two levels for very serious imprecision due to few participants, few events, and wide CIs. The study was published as a journal article. One study comparing ivermectin to standard of care reported viral clearance at 14 days in 40 participants with mild disease (Podder 2020). The study was not eligible for the primary analysis due the overall risk of bias assessment. The data of Podder 2020 with high risk of bias were included in a secondary analysis (Analysis 2.9). Ivermectin may have no e ect on viral clearance at 14 days compared to standard of care (RR 0.95, 95% CI 0.79 to 1.13; 1 study, 40 participants). The study was published as a journal article. No study reported data for SARS-CoV-2 infection (confirmed by RT-PCR or antigen testing) at 14 days. One study comparing ivermectin to no treatment reported the development of clinical COVID-19 symptoms at 14 days in 304 asymptomatic participants with household close contacts to confirmed COVID-19 index case (Shoumann 2021). The study result was not eligible for the primary analysis due to the overall risk of bias assessment. The data of Shoumann 2021 with high risk of bias were included in a secondary analysis (Analysis 3.1). Ivermectin may reduce the development of clinical COVID-19 symptoms in participants in contact with confirmed COVID-19 index cases compared to no treatment (RR 0.13, 95% CI 0.08 to 0.21; 1 study, 304 participants). The study was published as a journal article. One study comparing ivermectin to no treatment reported any adverse events within 14 days in 304 asymptomatic participants with household close contacts to confirmed COVID-19 index case n (Shoumann 2021). The study result was not eligible for the primary analysis due to the overall risk of bias assessment. The data of Shoumann 2021 with high risk of bias were included in a secondary analysis (Analysis 3.2). We are uncertain whether ivermectin increases or reduces any adverse events in participants in contact with confirmed COVID-19 index cases compared to no treatment (RR 11.50, 95% CI 0.68 to 193.21; 1 study, 304 participants). The study was published as a journal article. One study comparing ivermectin to no treatment reported mortality within 14 days in 304 asymptomatic participants with household close contacts to confirmed COVID-19 index case (Shoumann 2021). The study result was included in the primary meta-analysis due to the overall risk of bias assessment (Analysis 3.3). We are uncertain whether ivermectin reduces or increases mortality up to 28 days compared to no treatment as none of the participants in either group died (RR not estimable; 1 study, 304 participants; very low-certainty evidence). We downgraded the Cochrane Database of Systematic Reviews certainty of evidence one level for serious risk of bias and two levels for very serious imprecision due to zero events and few participants. The study was published as a journal article. No study reported data for admission to hospital. No study reported data for quality of life up to 14 days. This review included 14 studies with 1678 participants investigating ivermectin compared to placebo or standard of care. With intention to treat COVID-19, nine studies were conducted in inpatient settings with mainly moderate COVID-19 (WHO 4 to 5) and four studies in outpatient settings with mild COVID-19 (WHO 2 to 3). One study investigated ivermectin for the prevention of SARS-CoV-2 infection. The included studies contributed 41 study results to the review of which about one third were assessed at overall high risk of bias. The main findings of this review are summarized in Summary of findings 1 (treatment; inpatients), Summary of findings 2 (treatment; outpatients), and Summary of findings 3 (prevention). The number of studies per outcome was low. Only one or two studies per outcome provided useful data for our prioritized outcomes included in the summary of findings tables. Ivermectin showed no evidence of an e ect on increasing or decreasing mortality at 28 days, the most important outcome during this pandemic, neither in inpatients (two studies), outpatients (two studies), or the preventive setting (one study). The certainty for this finding was very low. The same accounts for clinical worsening up to 28 days in an inpatient setting and up to 14 days in an outpatient setting. With regard to clinical improvement, ivermectin may have little or no e ect compared to placebo or standard of care on clinical improvement up to 28 days and duration of hospitalizations in an inpatient setting. For outpatients, ivermectin may have little or no e ect on the number of participants with symptoms resolved up to 14 days. Based on very low certainty evidence, there was no significant increase in viral clearance at seven days in participants treated with ivermectin in inpatient settings and based on lowcertainty evidence for outpatient settings. For adverse events, ivermectin may have little or no di erence on occurrence of adverse events within 14 days in an outpatient setting, while we are uncertain about the e ect of ivermectin on adverse events within 28 days in an inpatient setting. The most significant outcome for participants not infected but at high risk of developing the infection following high-risk exposure was development of confirmed SARS-CoV-2 infection, which no studies reported. One study reported development of clinical COVID-19 symptoms, which we could not include in the primary analysis due to high risk of bias. The same accounted for adverse events within 14 days. Nine of 14 included studies were conducted in inpatient settings. However, participants mostly had moderate-severity COVID-19. Only one study included participants with severe COVID-19 requiring mechanical ventilation at baseline (Okumuş 2021). Therefore, the findings of this review are transferable to inpatients with moderate COVID-19 only. Four of 14 included studies were conducted in an outpatient setting with mild COVID-19 symptoms, though only two studies reported relevant outcomes and also had overall low risk or some concerns of bias (Chaccour 2021; López-Medina 2021). Based on the eligible study pool, there is currently no evidence available for the use of ivermectin in severely ill people with COVID-19 or those at high risk of disease progression. Most studies reported a mean age far below 60 years (overall mean age was 43 years with a mean range from 28 to 62 years) and included people with very few or no comorbidities (e.g. obesity). This major risk factor for severe COVID-19, was only reported in three studies (Chachar 2020; Krolewiecki 2020; López-Medina 2021). Considering age and pre-existing conditions as the most important risk factors for developing severe COVID-19, the current evidence is not applicable to patients who are at most risk of death from COVID-19. Hence, for outpatients as well as for inpatients we are still in need of good-quality trials in relevant populations to obtain evidence that would justify the use of ivermectin in regular patient care. In June 2021, the PRINCIPLE trialists announced inclusion of ivermectin in their platform trial, which might provide us with applicable data that helps to complete evidence for outpatient treatment (PRINCIPLE trial). Only 1 of 14 included studies investigated the potential of ivermectin for prevention of SARS-CoV-2 infection in people a er high-risk exposure. The study did not report results free of high risk of bias for one of the primary outcomes of interest for this review. Therefore, it is currently unclear whether ivermectin can prevent SARS-CoV-2 infection in people who have had a high-risk contact. Seven studies were conducted in Asia, four studies in South America, two in Europe, and one in Africa. In some countries where studies were conducted, uncontrolled ivermectin use is making it di icult to test the e ectiveness of the antiparasite drug against SARS-CoV-2 (Rodríguez-Mega 2020). With Chaccour 2021, only one study was conducted in a country with high healthcare expenditure. All studies administered ivermectin per mouth, but the doses and durations of administration varied. We set 200 µg/kg orally per day as the low dose based on the dosing recommendation for strongyloidiasis (WHO 2019). Four of the 14 studies used low doses in at least one study arm. All other studies utilized higher doses either in a single dose or over two to five days. Due to the small number of studies per outcome, we did not perform any subgroup analyses with low versus high doses and no evidence or clinical implication can be obtained regarding a certain dosing regimen. We found no studies that compared ivermectin to an active comparator with confirmed e icacy such as dexamethasone. Eight of the 14 studies had an open-label design and used no treatment or standard of care as comparators. Six studies were placebo-controlled studies. Standard of care must be comparable between the studies' arms. There are several studies circulating that investigate various concomitant medications (e.g. doxycycline, hydroxychloroquine, azithromycin, zinc) in addition to ivermectin. Due to unproven e icacy and possible adverse e ects, these comparisons may confound the assessment of the e icacy or safety of ivermectin, and we considered the inclusion of such Cochrane Database of Systematic Reviews combination therapies inappropriate. The same accounts for the comparison of ivermectin with an active comparator that has no proven e icacy in COVID-19. Although those types of interventions (e.g. hydroxychloroquine) were possibly used at a certain point of the pandemic with the best intentions, their use was never supported by actual evidence, and they have potential adverse e ects (Singh 2021). As we do not know the e ect of many of those experimental comparators in people with COVID-19, consequently no reliable evidence for ivermectin can be obtained from those comparisons either. Although 14 studies were eligible for the review questions, primary outcomes for studies with intention to treat COVID-19, as defined by the review, were only reported by a minority of studies. For some outcomes, di erent time points of outcome assessment or di erent outcome definitions prevented clinically useful pooling of the study results. Clinical worsening and improvement were heterogeneously reported, including outcomes that represent competing risks. Few studies followed the WHO Clinical Progression Scale (Marshall 2020). One study reported improvement and worsening of clinical status in an inpatient setting as the number of 'patients discharged without respiratory deterioration or death at 28 days' and as 'patients with respiratory deterioration or death at 28 days' (Gonzalez 2021). If reported at the same day, both outcomes give useful information on the clinical status of the study population in both directions -improvement and worsening -without containing competing risks. The outcome 'patients discharged without respiratory deterioration or death at 28 days' was deemed to be clinically useful and was added as a new primary outcome during preparation of this review. With further studies reporting these two very precise and unambiguous endpoints, evidence on ivermectin becomes more complete and patient-relevant. Finally, 31 studies are ongoing and 18 studies are awaiting classification due to an unpublished status or requiring clarification due to inconsistencies. When the studies are published or inconsistencies are clarified by study authors via personal communication, we will include them in a review update and conclusions of this review may change. Especially the most recently registered trials are proposing much larger numbers of participants than those of published trials so far. With group sizes ranging within the thousands, those trials may help to increase the certainty of evidence on the e icacy and safety of ivermectin. So far, we included only one study with intention to prevent SARS-CoV-2 infection. We identified several ongoing and unpublished studies focusing on this rationale. We are awaiting publication of those results to close the current gaps in the evidence on ivermectin used in postexposure prophylaxis. The certainty of evidence for prioritized outcomes presented in the summary of findings tables ranged from very low to low (Summary of findings 1; Summary of findings 2; Summary of findings 3). For the summary of findings and assessment of the certainty of the evidence according to Schünemann 2020, we used the results from the primary meta-analyses. Primary meta-analyses included only studies with low risk or some concerns of bias. We excluded studies at high risk of bias for their respective outcome and only analyzed them in secondary analyses to test the robustness of the results. One third of the study results were at overall high risk of bias. Most study results had some concerns for risk of bias. Two studies contributing five study results to four outcomes, including all-cause mortality, adverse events, and viral clearance at three and seven days, were at overall low risk of bias (Chaccour 2021; Mohan 2021). For the summary of findings, the certainty of evidence was downgraded one level due to serious risk of bias because most of the results were assessed as 'some concerns' of bias. Details of the risk of bias assessments per outcome are reported in Risk of bias in included studies. We could only include one study with overall low risk of bias on viral clearance at day seven in an outpatient setting in the primary analysis (Chaccour 2021). The certainty of evidence was not downgraded for study limitations. Nevertheless, this e ect estimate was associated with high uncertainty based on the low number of participants and few events. Another limitation for the certainty of evidence was the low number of participants, or events, or both, leading to wide CIs and high uncertainty of the estimated e ects. All outcomes included in the summary of findings tables were downgraded one or two levels for imprecision. Heterogeneity was rarely a reason to downgrade the certainty of evidence. This is mainly due to the small number of studies per meta-analysis. The only outcome with high heterogeneity (I 2 = 77%) included in the summary of findings tables was viral clearance at day seven in an inpatient setting. Two studies with conflicting results, one favouring ivermectin (Ahmed 2020), and one showing no important di erence between ivermectin and placebo (Mohan 2021), caused the high statistical heterogeneity. We did not downgrade any of the outcomes included in the summary of findings tables for indirectness. In all cases, the e ect estimates were based on comparisons of interest, on the population of interest, and on outcomes of interest. In the current phase of the pandemic, it is impossible to reliably assess the risk of publication bias. Most of the registered studies are still ongoing or, in the case of a completed study status, their results have not yet been published. We will follow the publication and trial history of each ongoing study and study awaiting classification. Currently, we did not suspect publication bias for any outcome included in this review. However, this may change in updates of this review. This review aimed to provide a complete evidence profile for ivermectin with regard to e icacy and safety for postexposure prophylaxis and treatment of COVID-19 based on current Cochrane standards (Higgins 2020a). Cochrane Database of Systematic Reviews ongoing studies as well as full publication of preprints closely a er the publication of this review. Five studies were preprint articles. We are aware that articles may change following peer-review. Nevertheless, we are convinced that including all eligible data in a highly dynamic situation such as the COVID-19 pandemic is crucial to be up-to-date and to provide timely information on potentially promising treatment options. Journal publications and corresponding preprint articles were compared in terms of consistency and all study results were assessed for their risk of bias. The immense amount of ongoing RCTs reflects the persistent lack of clarity on this intervention and the need for an update of this review. It should be considered that conclusions of the updated version di er from those of the present review. Review updates may allow for a more concise judgement of the e ectiveness and the safety of ivermectin for treatment and prevention of COVID-19. To minimise errors in screening, data extraction, and risk of bias assessment, two review authors independently conducted all processes. Analyses were conducted by one review author and checked by a second review author. We provided reasons for the exclusion of studies from this systematic review and described each included study in full detail and made explicit judgements on individual risk of bias. We contacted study authors if the publication included unclear or inconclusive information or in case of missing information. Unfortunately, not all attempts of gathering data were successful. Details of the communication with authors are provided in the Characteristics of included studies table. For three studies that had already published results, we could not finally judge eligibility due to inconsistencies in their study design description (Faisal 2020; NCT04407507; Samaha 2021). We contacted the corresponding authors to clarify those questions, though we have not received any satisfying response at the time of review publication. Another 15 trials classified as awaiting classification have not yet published results appropriately. We will monitor trials that have completed recruitment according to the trial registry closely for publication in the near future. None of the members of the review author team has any a iliation with any stakeholder group who favours or disapproves of ivermectin or the comparators used in relevant studies. Numerous reviews have been conducted investigating the e icacy of ivermectin for the treatment and prophylaxis of COVID-19 with inconsistent results in meta-analyses and conclusions, in many cases conflicting with our findings. Conflicts are mainly due to inclusion of studies investigating active comparators with unproven e icacy (e.g. hydroxychloroquine), pooling of studies with active and inactive comparators, di erent definitions of outcomes or outcomes assessment times, and di erent interpretations of the certainty of evidence. In this context, two groups are especially worth a mention, the Front Line COVID-19 Critical Care Alliance (FLCCC) and the British Ivermectin Recommendation Development (BIRD) group, which were, to some extent, founded and supported by the same scientists. Both groups and individual group associates conducted various systematic reviews and meta-analyses, all with conclusions strongly in favour of the e ectiveness of ivermectin for treatment and prevention of COVID-19 (BIRD 2021; Bryant 2021; Kory 2021). Additionally, there is an online and regularly updated analysis of published and emerging trials available (ivmmeta.com), postulating a strong beneficial e ect of ivermectin for people with COVID-19. The website does not provide authorship details, though states the FLCCC and BIRD as its resources. Hill and colleagues published another large systematic review in favour of ivermectin (Hill 2021). Main findings of the reviews and disagreements to our findings are briefly summarized in the following paragraphs. Hill 2021 identified 18 RCTs up to December 2020 and was a preprint article. The author team used the Cochrane Risk of Bias tool 1 for critical appraisal. However, the certainty of evidence was not assessed. Six RCTs investigating people with moderate-tosevere COVID-19 were pooled for the meta-analysis on mortality with a benefit of 75% for ivermectin (RR 0.25, 95% CI 0.12 to 0.52). Hill 2021 compared ivermectin alone or in combination with doxycycline to control interventions, including placebo, standard of care, or hydroxychloroquine, and pooled all in one comparison. We did not include five of the six studies in our meta-analysis on mortality of people with moderate COVID-19, including Elgazzar 2020, Hashim 2020, Mahmud 2021, Niaee 2020, and Okumuş 2021. Hashim 2020 and Mahmud 2021 combined ivermectin with doxycycline, which makes it impossible to isolate any potential e ect to the individual drugs used. Elgazzar 2020 compared ivermectin to hydroxychloroquine. The latter is not e ective for the treatment of COVID-19 and has resulted in clinical adverse e ects (Singh 2021). We did not consider hydroxychloroquine an eligible comparator to investigate the e icacy and safety profile of ivermectin for the treatment of COVID-19. Niaee 2020 included a population of about 30% of people who were SARS-CoV-2-negative, which we did not consider appropriate to investigate SARS-CoV-2specific antiviral e ect of ivermectin. Okumuş 2021 compared ivermectin to an eligible comparator and investigated an eligible population, but reported mortality at an ineligible time point (e.g. on average three months). Finally, there is only one small study with broad CIs and high uncertainty for a mortality benefit (RR 0.12, 95% CI 0.01 to 2.09), which is also included in our meta-analysis on mortality of people with moderate COVID-19 (Kirti 2021). However, we included mortality at day 28 rather than in-hospital mortality, which was di erent in one participant who died in the control group. Kory 2021 identified seven RCTs on the e icacy of ivermectin in outpatients with mild COVID-19 and six RCTs in hospitalized people with COVID-19. The review was published in the American Journal of Therapeutics and did not provide any search date or other methodological details used for meta-analyses. Kory 2021 concluded there was a mortality benefit based on the inclusion of six of the 13 studies (odds ratio (OR) 0.13, 95% CI 0.07 to 0.28), which was not a valid inclusion because Elgazzar 2020, Hashim 2020, Mahmud 2021, and Niaee 2020 were not eligible for the reasons described above, and Cadegiani 2020 was not an RCT. As described for Hill 2021, there remains only one small study (Kirti 2021), and a high degree of uncertainty for a mortality benefit. Cochrane Database of Systematic Reviews they followed the Cochrane's rapid review template and had a review protocol that was not registered on an appropriate register (e.g. PROSPERO). The author team used the Cochrane Risk of Bias tool 1 for critical appraisal and GRADE to assess the certainty of evidence. A meta-analysis of 15 trials found that ivermectin reduced the risk of death by an average of 62% compared with no ivermectin treatment (RR 0.38, 95% CI 0.19 to 0.73). The certainty of evidence was moderate due to study design limitations. The author team conducted several sensitivity analyses excluding outlier studies, studies at high risk of bias, and studies with active comparators. The e ect estimates remained robust. However, even the sensitivity analysis excluding studies with active comparators, which was the most comparable analysis to our analysis on mortality, based their conclusion on studies that did not meet eligibility criteria for this current Cochrane Review (RR 0.41, 95% CI 0.23 to 0.74). Hashim 2020 and Mahmud 2021 combined ivermectin with doxycycline. Niaee 2020 and Rezai 2020 (Shahbaznejad 2021) included a mixed population with about 30% (Niaee 2020) and 75% (Rezai 2020 (Shahbaznejad 2021)) of participants with negative SARS-CoV-2 PCR tests. The registry entry of Petkov 2020 (2020-002091-12/BG) was eligible for our review, though there is no scientific publication of results except a press release on the manufacturer's website. Okumuş 2021 and Mohan 2021 reported mortality at an ineligible time point and Ahmed 2020 did not report mortality in the journal publication. Finally, the four remaining studies were included in our meta-analyses for outpatients (Chaccour 2021; López-Medina 2021) and inpatients (Gonzalez 2021; Kirti 2021) with COVID-19. All studies had broad CIs with a high uncertainty for a mortality benefit. Moreover, Bryant 2021 used a trial sequential analysis to test whether there was su icient evidence to detect or reject intervention e ects and to address imprecision of the e ect estimates in this way. They concluded that there may have been su icient evidence accrued before the end of 2020 to show a significant benefit of ivermectin over control for all-cause mortality. However, trial sequential analysis cannot adjust for risk of bias or wrong comparators. Therefore, inclusion of all trials in this context into the analysis does not yield reliable results. Even if not eligible for the Cochrane Review, two studies in Bryant 2021 and all the other meta-analyses were notable because of the size of the e ect reported and the narrow CIs: Elgazzar 2020 and Niaee 2020 help drive the large e ects seen in the random-e ects analysis. Elgazzar 2020, for example, reported among people with severe disease two deaths out of 100 in the ivermectin group and 20 deaths out of 100 in the chloroquine group; and Niaee 2020 reported two deaths out of 100 in the ivermectin group and 11 deaths out of 60 in the control group. These e ect sizes are extreme. A recent press release claimed that the large trial by Elgazzar 2020 showed clear signs of fraudulence and should be withdrawn over ethical concerns (The Guardian 2021). Research Square withdrew this preprint on 14 July 2021 due to an expression of concern (Elgazzar 2020). The website ivmmeta.com provides several meta-analyses of pooled e ects including up to 60 studies. This website shows pooled estimates suggesting significant benefits with ivermectin, which has resulted in confusion for clinicians, patients, and decision-makers (Garegnani 2021). The analyses are misleading and have several limitations. As described for the other reviews, several ineligible interventions and comparators were pooled. Additionally, di erent outcomes were pooled and reported as percentage improvement with ivermectin studied in RCTs ranging from 40% improvement when used as late treatment to 83% improvement when used as prophylaxis. However, there is no full prospective protocol available describing the relevant review methodology, and there is no assessment of the risk of bias or the certainty of evidence. National and international guidelines regarding the use of ivermectin for the treatment or prevention of Based on the current very low-to low-certainty evidence, we are uncertain about the e icacy and safety of ivermectin used to treat people with COVID-19 in the inpatient and outpatient settings and to prevent a SARS-CoV-2 infection in people a er having high-risk exposure. There is also no evidence available from the study pool as to which is the best dose and regimen of ivermectin. Overall, the reliable evidence available does not support the use ivermectin for treatment or prevention of COVID-19 outside of well-designed randomized controlled trials (RCTs). With respect to the number of identified studies in trial registries and with accordance to the living approach of this review, we will continually update our search and include eligible trials. There remains insu icient evidence regarding the e icacy and safety of ivermectin used for the treatment of people with COVID-19 in the inpatient and outpatient settings and to prevent SARS-CoV-2 infection in people a er high-risk exposure. Based on our review, we define the following gaps in the evidence. • High-quality RCTs: double-blind, placebo-controlled, randomized studies with su icient power and conducted in accordance to the CONSORT 2010 Statement. Currently, there is an urgent need for good-quality evidence, based on RCTs with appropriate randomization procedures, comparability of study arms, and a preferably double-blind design. We identified 31 ongoing RCTs in trial registries and another 18 studies which are potentially eligible but have either not published their results yet or where we require additional clarifications from the study investigators. The findings from these studies may help to answer more clearly the question of ivermectin and its e ects in treating and preventing COVID-19 in the future. In accordance with the living approach of this review, we will continually update our search and include eligible trials. The Academic Editor is Dr Hellen Gelband, and Sign-o Editor is Professor Lisa Bero. Pennine Acute Hospitals NHS Trust (review stage). We thank Anne Lawson (Cochrane Copy Editor) for copy editing the review. This review was partly developed in the framework of the CEOsys (COVID-19 Evidence Ecosystem) project. We thank those involved at CEOsys for their support (covid-evidenz.de/). Moreover, we thank the Cochrane Haematology working group for contributing to this review. The research was part of a project supported by the Federal Ministry of Education and Research (NaFoUniMedCovid19, funding number: 01KX2021; part of the CEOsys project). The contents of this document reflect only the review authors' views and the German Ministry is not responsible for any use that may be made of the information it contains. The CIDG editorial base is funded by UK aid from the UK Government for the benefit of low-and middle-income countries (project number 300342-104 IRCT20200408046987N3. Evaluation of prophylaxis induced by ivermectin in populations exposed to COVID-19 patients. www.irct.ir/trial/51999 (first received 6 December 2020). Cochrane LSR. Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode. Available from community.cochrane.org/reviewproduction/production-resources/living-systematic-reviews (accessed 22 March 2021). Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine 2010;8:18. Covid Management Guidelines India Group. COVID Management Guidelines India. indiacovidguidelines.org/ivermectin/ (accessed 15 May 2021). COVID-NMA working group. The COVID-NMA initiative: a living mapping and living systematic review of Covid-19 trials. covidnma.com (accessed prior to 1 July 2021). Deeks JJ, Higgins JP, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins European Medicines Agency. EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials. ema.europa.eu/en/news/emaadvises-against-use-ivermectin-prevention-treatment-covid-19outside-randomised-clinical-trials (accessed 15 May 2021). Cochrane Database of Systematic Reviews veterinary/product-safety-information/faq-covid-19-andivermectin-intended-animals (accessed 19 February 2020). Garegnani Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/ v6.1. Higgins JP, Eldridge S, Li T. Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1. Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/ v6.1. Higgins JP, Li T, Deeks JJ (editors). Chapter 6: Choosing e ect measures and computing estimates of e ect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/ v6.1. Higgins MAGICapp. MAGIC, 2020. Available at magicevidence.org/ magicapp/. Marshall Merck. Merck statement on ivermectin use during the COVID-19 pandemic. merck.com/news/merck-statement-on-ivermectinuse-during-the-covid-19-pandemic/ (accessed 15 May 2021). cran.r-project.org/web/packages/meta Meta: general package for meta-analysis. cran.r-project.org/web/packages/meta, 2021. Available at cran.r-project.org/web/packages/meta/meta.pdf. COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. www.covid19treatmentguidelines.nih.gov/ (accessed 19 February 2021). Oran DP, Topol EJ. The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review. Annals of Internal Medicine 2021;174 (5) University of Oxford. Ivermectin to be investigated in adults aged 18+ as a possible treatment for COVID-19 in the PRINCIPLE trial. principletrial.org/news/ivermectin-to-be-investigated-as-a-possible-treatment-for-covid-19-in-oxford2019s-principletrial (accessed 1 July 2021). Recovery Cochrane Database of Systematic Reviews supporting-ivermectin-as-covid-treatment-withdrawn-overethical-concerns (accessed 15 July 2021). Wagsta KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochemical Journal 2012;443 (3) World Health Organization. WHO model list of essential medicines, 21st list. www.who.int/medicines/publications/ essentialmedicines/en (accessed 19 February 2021). World Health Organization. WHO coronavirus disease (COVID-19) dashboard. covid19.who.int/ (accessed 2 July 2021). World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guidance, 11 September 2020. Available at https:// apps.who.int/iris/handle/10665/334253. World Health Organization. Weekly epidemiological update -19 January 2021. www.who.int/publications/m/item/weekly-epidemiological-update---19-january-2021 (accessed 19 February 2021). World Health Organization. Therapeutics and COVID-19. Living guideline. who.int/publications/i/item/WHO-2019-nCoVtherapeutics-2021.1 (accessed 3 June 2021). Williamson • • Inclusion criteria: men or women, aged ≥ 18 years; tested positive after completion of standard care treatment for SARS-CoV-2 confirmed by RT-PCR assay; mild symptoms or asymptomatic; no comorbidities affecting the patient's prognosis, rendering them at high risk; documented acceptance to participate by means of the execution of the informed consent • Exclusion criteria: allergy or hypersensitivity to ivermectin or its inactive ingredients, or both; respiratory distress or requiring intensive care; used immunosuppressants (including systemic corticosteroids) in the last 30 days; known HIV infection with CD4 count < 300 cell/L; pregnancy or lactating women; medical conditions such as mal-absorption syndromes affecting proper ivermectin absorption; autoimmune disease or decompensated chronic diseases, or both; uncontrolled, intercurrent diseases including renal impairment, hepatic impairment, symptomatic congestive heart failure, unstable chest angina, or heart arrhythmia; treated in any other study in the previous 30 days; concomitant administration of enzyme inducers (such as carbamazepine) that could affect the effectiveness of the drug and people receiving CYP3A4 substrates (such as statins) due to the risk of increased toxicity Cochrane Database of Systematic Reviews of the execution of the informed consent; women of childbearing age must have a negative pregnancy test and use adequate contraceptive methods during participation in the study and for 1 month after the last medication dose in the case of those receiving ivermectin • Exclusion criteria: allergy or hypersensitivity to ivermectin or its inactive ingredients, or both; people meeting COVID-19 severity criteria, with respiratory distress or requiring intensive care; using medications having potential activity against SARS-CoV-2 such as hydroxychloroquine, chloroquine, lopinavir, ritonavir, remdesivir, or azithromycin in the last 3 months; use of immunodepressants (including systemic corticosteroids) in the last 30 days; known HIV infection with CD4 count < 300 cell/µL; pregnancy or lactating; other infectious diseases or medical conditions such as malabsorption syndromes affecting proper ivermectin absorption; acute allergy conditions or with severe allergic reactions background; autoimmune disease or decompensated chronic diseases, or both; uncontrolled, intercurrent diseases including renal impairment, hepatic impairment, symptomatic congestive heart failure, unstable chest angina, heart arrhythmia or psychiatric conditions that may limit adherence to CT requirements • Severity of condition according to study definition: mild disease, defined as being at home or hospitalized but not receiving high-flow nasal oxygen or mechanical ventilation • Severity of condition according to WHO scale: 2 to 3 (< 1% of included patients 4 to 5) • Co-morbidities: any pre-existing condition, obesity, diabetes, hypertension, respiratory disease • Virus detection performed at baseline (test-positive at baseline): RT-PCR or rapid antigen test (100%) • Inclusion criteria: aged ≥ 18 years; confirmed SARS-CoV-2 by RT-PCR or antigen detection in a Colombian NIH-approved laboratory; beginning of symptoms in the past 7 days; mild disease; informed consent • Exclusion criteria: pre-existing liver disease; hypersensitivity to ivermectin; participants in other clinical trials for therapies against COVID-19; severe pneumonia; pregnant or breastfeeding women; concomitant use of warfarin, erdafitinib, or quinidine; use of ivermectin in the 5 days prior to randomization; inability to obtain a blood sample needed to assess liver transaminases; elevation of transaminases > 1.5 times the normal level; participant whose first contact with the study personnel occurs between days 5 and 7 and at that time manifests significant and progressive resolution of COVID-19 related signs and symptoms • Inclusion criteria: hospitalized and a prediagnosis of 'severe COVID-19 pneumonia' and thereafter diagnosis of COVID-19 was also confirmed microbiologically with PCR positivity in respiratory tract samples; ≥ 1 of the following criteria were accepted as severe COVID-19 pneumonia: presence of tachypnoea ≥ 30 breaths/minute; SpO 2 level < 90% in room air; PaO 2 /FiO 2 < 300 in oxygen-receiving participant; presence of specific radiological finding for COVID-19 in lung tomography; mechanical ventilation requirement; acute organ dysfunction findings; people with sepsis-related organ failure assessment score > 2 • Exclusion criteria: aged < 18 years; chronic liver or kidney disease; pregnancy; known ivermectin allergy; for modified intention-to-treat analysis mutation, carriers were excluded after randomization Active comparator: ivermectin compared to a control (lopinavir/ritonavir) with unknown influence on COVID-19, which we did not consider eligible to determine ivermectin's true effect. Wrong study design: case-control study. Cadegiani 2020 Wrong study design: historical control group, i.e. no RCT. Camprubi 2020 Wrong study design: retrospective study. Carvallo 2020 Wrong study design: prospective cohort study; additionally ivermectin was administered in combination with other active drugs with unknown influence on COVID-19. Combined intervention: ivermectin administered in combination with another active substance (iota-carrageenan) with unknown influence on prevention of COVID-1,9 which we did not consider eligible to determine ivermectin's true effect. Wrong study design: cluster-randomised trial. Combined intervention: ivermectin administered in combination with another active drug (doxycycline) with unknown influence on COVID-19, which we did not consider eligible to determine ivermectin's true effect. Additionally, the study used an active comparator with unproven efficacy (hydroxychloroquine + azithromycin). CTRI/2020/08/027282 Active comparator: ivermectin compared to a control (vitamin supplements) with unknown influence on COVID-19, which we did not consider eligible to determine ivermectin's true effect. CTRI/2020/08/027394 Active comparator: ivermectin compared to a control (chloroquine/azithromycin/vitamin supplements) with unknown influence on COVID-19, which we did not consider eligible to determine ivermectin's true effect. • Inclusion criteria * People aged > 50 years with comorbidities, diagnosed with SARS-CoV-2 infection by PCR or another diagnostic test performed in the emergency department, who are in the first week of clinic, without pneumonia and without admission criteria * People aged 18-70 years inclusive with pneumonia associated to SARS-Co2 infection: cough or expectoration or fever > 38 °C with or without radiological infiltrate in Rxtórax; with SARS-CoV-2 PCR or radiological, clinical and analytical findings of COVID-19 * Evolution time of initial symptoms between 3 and 8 days * Basal oxygen saturation ≥ 93% by breathing ambient air * Have signed the informed consent • Exclusion criteria * People with pneumonia due to SARS-CoV-2 that requires hospital admission, due to multilobar involvement, respiratory failure PO 2 < 93% ambient air or < 92% for people with COPD; with analytical criteria of severity (D-dimer > 600, CRP > 50, lymphopenia < 900, ferritin > 700 mg/dL, interleukin-6 or organ failure of the organ or who have significant comorbidities: renal insufficiency > 3B; immunosuppression, cancer; chronic cirrhosis or liver disease, diabetes mellitus, atherosclerosis of any territory, heart rhythm disturbances (including prolonged QT), poorly controlled hypertension) * People with QT range > 500 mseconds * People aged < 18 years * Child-Pugh C liver failure * Impossibility of giving treatment for non-suppressible drugs with the risk of QT prolongation or interactions (antidepressants, antihistamines, quinolones, statins except pitavastatin) or allergy to the drug * Taking any of the drugs in the trial within 7 days prior to inclusion in the study * Pregnancy, lactation • Details of intervention * Type and dose: ivermectin 0.2-0.4 mg/kg, no details on frequency scheme * Route of administration: oral • Treatment details of control group * Placebo, azithromycin, hydroxychloroquine are named in the protocol as comparatory, but unclear design of study arms • Concomitant therapy: unclear • Primary study outcome * Efficacy will be measured by comparing clinical cure, microbiology, need for hospital admission due to clinical or analytical, blood gas, radiological deterioration, or a combination of these for each arm. • Relevant review outcomes planned * To assess the clinical cure rate after 2 weeks of treatment * To evaluate the microbiological cure rate 72 hours after treatment * To analyze adverse events to treatment Participants • Inclusion criteria * Men or women aged ≥ 18 years * Signed informed consent * Admitted to hospital for treatment of COVID-19 * Hospitalization must be for medical and not for social reasons * Patient within 7 days from symptom onset and within 72 hours after laboratory diagnosis (SARS-CoV-2 RT-PCR) * Mild-to-moderate COVID-19 disease defined as clinical status category 3 or 4 on the WHO 9point ordinal scale □ Hospitalized, no oxygen treatment □ Oxygen by mask or nasal prongs * Presence of ≥ 1 symptom characteristic for COVID-19 disease, e.g. fever, cough, sore throat, myalgia, fatigue, gastrointestinal; disorders, skin lesions, etc. * In women of childbearing potential, negative pregnancy test and commitment to use contraceptive method throughout study Library Trusted evidence. Informed decisions. Better health. • Exclusion criteria * Critical patients with expected survival time < 72 hours * Presence of respiratory failure, shock, combined failure of other organs that requires ICU monitoring, or a combination * Participation in the trial is not in the person's best interest based on the judgement of the investigator * Presence of the following laboratory values at screening □ White blood cell count < 1.5 × 10 9 /L □ Platelet count < 100,000 mm 3 (< 1.00 × 10 9 /L) □ Total bilirubin > 2 × ULN □ ALT or GGT > 3 × ULN * Clinical suspicion for a bacterial superinfection at screening * Allergic or hypersensitive to the investigational medicinal product or any of the ingredients * Patients who cannot take drugs orally, or have severe gastro-intestinal disorders, extensive bowel resection or bowel obstruction * Previous (in the past 3 months) or concurrent use of any other investigational product * Use of the prohibited medications during the treatment with investigational product, as defined in the protocol * People with end-stage liver disease (Child-Pugh C score) * History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (New York Heart Association class III or IV) * Presence of acute stroke at screening or a history of acute stroke within the last 6 months * Pregnant or breastfeeding * Legal incapacity, limited legal capacity, or any other condition that makes the patient unable to provide consent for the trial * Patients who are institutionalized due to judicial order * Employee or immediate relative of the investigator or sponsor * Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including asthma and COPD), renal, hepatic, endocrine (including uncontrolled diabetes mellitus) or gastrointestinal disorder, that according to investigator could jeopardize the safety of the patient, or the integrity of the study • Inclusion criteria * Adults aged ≥ 18 years with COVID-19. A positive throat swab (by RT-PCR) obtained from a person suspected to have COVID-19 or from a contact (or healthcare worker) of people with COV-ID-19 will be considered to be a COVID-19 case. * Presence of moderate COVID-19 disease as defined by presence of pneumonia (clinical and radiological signs) with respiratory rate 15-30 per minute or SpO 2 90-94% on room air. • Exclusion criteria * People with renal or hepatic dysfunction (serum creatinine > 1.5 mg/dL and serum transaminase levels > 120 U/L) * People with clinical heart failure/known coronary artery disease * Known cases of neoplasms or immunodeficiency syndromes * People receiving chemotherapy, immunosuppressive agents, steroids, or antiviral agents, or have received in the preceding 4 weeks * Pregnant and lactating women * Uncooperative patients (in the opinion of the investigator, if it is difficult to ensure patient cooperation during the study) Cochrane Database of Systematic Reviews • Additional study outcomes * Reduction in inflammatory markers at days 1, 5, and 10 * Resolution of signs and symptoms of COVID-19 at 3, 5, and 10 days • Reason for awaiting classification: unclear study design and fulfilment of randomization criteria; author request sent (even though the term randomization is used, within the method section the study is described as 'cross-sectional;' additionally the definition of being symptom-free and the method of assuring symptom resolution at a certain day needs to be clarified); no response received from the author • Date of publication: 15 October 2020 • Sponsor/funding: no funding • Inclusion criteria * Age ≥ 18 years * Laboratory-confirmed SARS-CoV-2 infection within the past 7 days or the presence of symptoms or physical examination signs providing high probability of COVID-19 disease * Must have adequate organ and marrow function measured within the last 6 months * Must have ≥ 1 of the following high-risk features or clinical deterioration: hypertension, diabetes mellitus, moderate-to-severe COPD, emphysema, cystic fibrosis, or asthma; people with cancer who have received any immunosuppressive drugs within 1 year from enrolment, sickle cell disease or thalassaemia, age ≥ 50 years, BMI ≥ 30, living in a nursing home or long-term facility, underlying serious heart condition as determined by the treating physician, immunocompromised person as defined by the treating physician or COVID-19 Telehealth Treatment Team • Exclusion criteria * Severe or life-threatening COVID-19 * Weight < 45 kg * Pregnant or breastfeeding women * Receiving dialysis or with creatinine clearance < 45 mL/minute * Existing Division of Microbiology and Infectious Diseases Toxicity Scale for Determining Severity of Adverse Events grade ≥ 3 hepatic failure * Previously documented moderate or severe retinopathy or macular degeneration * Uncontrolled seizure disorder * Prolonged QT, defined as QTc ≥ 470 mseconds for men and QTc ≥ 480 mseconds for women using Bazett's formula * Known allergy to artesunate, artemisia annua, hydroxychloroquine, macrolides, 4-aminoquinolines, camostat mesilate, or other agents to be used in the trial * Currently receiving any study medications for other indications * Concurrent use of medication that would cause drug-drug interactions * Psychiatric illness/social situations that would limit compliance • Severity of condition according to study definition: outpatients with mild or no symptoms • Severity of condition according to WHO scale: 1 to 3 • Co-morbidities: NR • Virus detection performed at baseline (test-positive at baseline): NR, but RT-PCR positivity defined as inclusion criterion • Inclusion criteria: diagnosis of acute severe respiratory syndrome due to SARS-CoV-2 coronavirus infection defined by RT-PCR; asymptomatic, or with mild symptoms who are taking outpatient treatment of the disease; signed informed consent • Exclusion criteria: severe disease COVID-19; positive to proof of infection by some other virus such as influenza H1N1, severe acute respiratory syndrome, etc.; recurrent urinary tract infections; ALT or AST > 5 times above its normal limits; pregnant or lactating; receiving antihypertensive medication verapamil, the immunosuppressant cyclosporin A or the antipsychotic trifluoperazine, or both; known allergy or hypersensitivity to dewormers; using an antioxidant supplement; history of filariasis, strongyloidiasis, scabies, river blindness, or any parasitic disease in the last 12 months • Details of intervention of relevant arms * Type and dose: ivermectin 12 mg, once daily for 3 days * Route of administration: oral • Treatment details of control group * Placebo with standard of care • Concomitant therapy: standard of care including paracetamol administered in both study arms • Duration of follow-up: 21 days • Treatment cross-overs: none • Primary study outcome * Participants with a disease control status defined as no disease progression to severe at 14 days • Relevant review outcomes reported * Adverse events within 21 days * Serious adverse events within 21 days * Mortality at 21 days * Need for invasive mechanical ventilation at 14 days • Additional study outcomes reported * SARS-CoV-2 viral load at 5 and 14 days * Presence and frequency of symptoms associated with the COVID-19 disease within 14 days Notes • Reason for awaiting classification: unclear study design; author request sent (even though the register entry and study protocol use the term randomization, the method of assignment described in the study protocol does not seem to fulfil randomization criteria); no response received from the author • Inclusion criteria * Participant (or legally authorized representative) provides written informed consent prior to initiation of any study procedures * Understands and agrees to comply with planned study procedures * Agrees to the collection of oropharyngeal swabs and venous blood per protocol * Male or non-pregnant female adult age ≥ 18 years at enrolment * Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other * Severe cases according to WHO definition • Exclusion criteria * ALT/AST > 5 times the ULN * Mortality within 12 hours of admission * Pregnancy * Anticipated transfer to another hospital within 24 hours * Allergy to any study medication commercial or public health assay in any specimen prior to randomization * Mechanically ventilated on admission • Details of intervention for relevant arms: * Type and dose: ivermectin 12 mg, thrice daily on day 0, 3, and 6 * Route of administration: oral • Inclusion criteria * Substudy treatment □ Symptomatic (respiratory) participants with a positive RT-PCR test for COVID-19 and a clinical condition of < 5 days of evolution □ Age ≥ 18 years □ In women of childbearing age, negative pregnancy test and use of contraceptive method during the study period □ Accept to take the medication and the complementary test procedures during the study, including analysis and nasal sampling □ Able to provide informed consent (oral or written) * Substudy prevention □ Contacts of symptomatic (respiratory) people with a positive RT-PCR test for COVID-19 and a diagnosis of < 5 days of evolution □ Of legal age □ In women of childbearing age, negative pregnancy test and use of contraceptive method during the study period □ Accept to take the medication and the complementary test procedures during the study, including analysis and nasal sampling □ Able to provide informed consent (oral or written) • Inclusion criteria * People aged ≥ 50 years who have tested positive for SARS-CoV-2 (by any NAAT/PCR-based testing system recognized by public health authorities) within the preceding 12 days * Are still symptomatic or have not yet developed symptoms * Have any of the following risk factors: take medication for hypertension, take medication (oral or injectable) for blood glucose control, take medication for heart disease, take medication (oral or inhaled) for lung disease, currently smoke * Are residing in the community * Have at their current place of residence (i.e. at the location they are maintained in isolation) communication facilities necessary for trial functioning, these are: reliable mobile or landline telephone (or both) access, reliable access to email (1) Time point (28 days), participants (WHO 5), intervention (ivermectin 12 mg or 18 mg daily for 5 days), comparator (placebo) (2) Time point (28 days), participants (WHO 4 to 5), intervention (ivermectin 12 mg daily for 2 days), comparator (placebo) (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: All-cause mortality up to 28 days (primary analysis) (C) Bias due to missing outcome data: All-cause mortality up to 28 days (primary analysis) (D) Bias in measurement of the outcome: All-cause mortality up to 28 days (primary analysis) (E) Bias in selection of the reported result: All-cause mortality up to 28 days (primary analysis) (F) Overall bias: All-cause mortality up to 28 days (primary analysis) Analysis 1.2. Comparison 1: Ivermectin compared to placebo or standard of care for people with moderate-to-severe COVID-19 treated in the inpatient setting, Outcome 2: Worsening of clinical status -need for invasive mechanical ventilation up to 28 days (primary analysis) (1) Time point (28 days), participants (WHO 5), intervention (ivermectin 12 mg or 18 mg daily for 5 days), comparator (placebo) (2) Time point (28 days), participants (WHO 4 to 5), intervention (ivermectin 12 mg daily for 2 days), comparator (placebo) (1) Time point (28 days), participants (WHO 5), intervention (ivermectin 12 mg or 18 mg daily for 5 days), comparator (placebo) Risk of bias legend (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Improvement of clinical status -participants discharged without respiratory deterioration or death at 28 days (primary analysis) (C) Bias due to missing outcome data: Improvement of clinical status -participants discharged without respiratory deterioration or death at 28 days (primary analysis) (D) Bias in measurement of the outcome: Improvement of clinical status -participants discharged without respiratory deterioration or death at 28 days (primary analysis) (E) Bias in selection of the reported result: Improvement of clinical status -participants discharged without respiratory deterioration or death at 28 days (primary analysis) (F) Overall bias: Improvement of clinical status -participants discharged without respiratory deterioration or death at 28 days (primary analysis) (1) Time point (14 days), participants (WHO 4 to 5 incl. asymptomatic people), intervention (ivermectin 12 mg and 24 mg, single dose), comparator (placebo) (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Any adverse events within 28 days (primary analysis) (C) Bias due to missing outcome data: Any adverse events within 28 days (primary analysis) (D) Bias in measurement of the outcome: Any adverse events within 28 days (primary analysis) (E) Bias in selection of the reported result: Any adverse events within 28 days (primary analysis) (F) Overall bias: Any adverse events within 28 days (primary analysis) Analysis 1.6. Comparison 1: Ivermectin compared to placebo or standard of care for people with moderate-tosevere COVID-19 treated in the inpatient setting, Outcome 6: Any adverse events within 28 days (secondary analysis) (1) Time point (30 days), participants (WHO 4 to 5), intervention (ivermectin 0.6 mg/kg/day, 3 mg or 6 mg daily for 5 days), comparator (standard of care) (2) Time point (14 days), participants (WHO 4 to 5 incl. asymptomatic people), intervention (ivermectin 12 mg and 24 mg, single dose, oral), comparator (placebo) (3) Time point (28 days), participants (unclear, min. WHO 4, 20% WHO 5), intervention (ivermectin 0.1 mg/kg, 0.2 mg/kg, and 0.4 mg/kg over 72 h), comparator (standard of care) (4) Time point (28 days), participants (WHO 4 to 5), intervention (ivermectin 12 mg, single dose), comparator (standard of care) (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Any adverse events within 28 days (secondary analysis) (C) Bias due to missing outcome data: Any adverse events within 28 days (secondary analysis) (D) Bias in measurement of the outcome: Any adverse events within 28 days (secondary analysis) (E) Bias in selection of the reported result: Any adverse events within 28 days (secondary analysis) (F) Overall bias: Any adverse events within 28 days (secondary analysis) (1) Time point (30 days), participants (WHO 4 to 5), intervention (ivermectin 0.6 mg/kg/day, 3 mg or 6 mg daily for 5 days), comparator (standard of care) (2) Time point (14 days), participants (WHO 4 to 5 incl. asymptomatic people), intervention (ivermectin 12 mg and 24 mg, single dose), comparator (placebo) (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Serious adverse events within 28 days (primary analysis) (C) Bias due to missing outcome data: Serious adverse events within 28 days (primary analysis) (D) Bias in measurement of the outcome: Serious adverse events within 28 days (primary analysis) (E) Bias in selection of the reported result: Serious adverse events within 28 days (primary analysis) (F) Overall bias: Serious adverse events within 28 days (primary analysis) Analysis 1.8. Comparison 1: Ivermectin compared to placebo or standard of care for people with moderate-to-severe COVID-19 treated in the inpatient setting, Outcome 8: Serious adverse events within 28 days (secondary analysis) (1) Time point (14 days), participants (WHO 4), intervention (ivermectin 12 mg daily for 5 days), comparator (placebo) (2) Time point (30 days), participants (WHO 4 to 5), intervention (ivermectin 0.6 mg/kg/day, 3 mg or 6 mg daily for 5 days), comparator (standard of care) (3) Time point (14 days), participants (WHO 4 to 5 incl. asymptomatic people), intervention (ivermectin 12 mg and 24 mg, single dose), comparator (placebo) Risk of bias legend (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Serious adverse events within 28 days (secondary analysis) (C) Bias due to missing outcome data: Serious adverse events within 28 days (secondary analysis) (D) Bias in measurement of the outcome: Serious adverse events within 28 days (secondary analysis) (E) Bias in selection of the reported result: Serious adverse events within 28 days (secondary analysis) (F) Overall bias: Serious adverse events within 28 days (secondary analysis) (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Admission to intensive care unit (primary analysis) (C) Bias due to missing outcome data: Admission to intensive care unit (primary analysis) (D) Bias in measurement of the outcome: Admission to intensive care unit (primary analysis) (E) Bias in selection of the reported result: Admission to intensive care unit (primary analysis) (F) Overall bias: Admission to intensive care unit (primary analysis) Analysis 1.10. Comparison 1: Ivermectin compared to placebo or standard of care for people with moderateto-severe COVID-19 treated in the inpatient setting, Outcome 10: Duration of hospitalization (primary analysis) (1) Time point (3 days), participants (WHO 4), intervention (ivermectin 12 mg daily for 5 days), comparator (placebo) (2) Time point (3 days), participants (WHO 4 to 5 incl. asymptomatic people), intervention (ivermectin 12 mg and 24 mg, single dose), comparator (placebo) (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Viral clearance at 3 days (primary analysis) (C) Bias due to missing outcome data: Viral clearance at 3 days (primary analysis) (D) Bias in measurement of the outcome: Viral clearance at 3 days (primary analysis) (E) Bias in selection of the reported result: Viral clearance at 3 days (primary analysis) (F) Overall bias: Viral clearance at 3 days (primary analysis) Analysis 1.12. Comparison 1: Ivermectin compared to placebo or standard of care for people with moderateto-severe COVID-19 treated in the inpatient setting, Outcome 12: Viral clearance at 3 days (secondary analysis) (1) Time point (3 days), participants (WHO 4), intervention (ivermectin 12 mg daily for 5 days), comparator (placebo) (2) Time point (3 days), participants (WHO 4 incl. asymptomatic people), intervention (ivermectin 12 mg , single dose), comparator (standard of care) (3) Time point (3 days), participants (WHO 4 to 5 incl. asymptomatic people), intervention (ivermectin 12 mg and 24 mg, single dose), comparator (placebo) (4) Time point (3 days), participants (WHO 4 to 5), intervention (ivermectin 12 mg, single dose), comparator (standard of care) (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Viral clearance at 3 days (secondary analysis) (C) Bias due to missing outcome data: Viral clearance at 3 days (secondary analysis) (D) Bias in measurement of the outcome: Viral clearance at 3 days (secondary analysis) (E) Bias in selection of the reported result: Viral clearance at 3 days (secondary analysis) (F) Overall bias: Viral clearance at 3 days (secondary analysis) (1) Time point (7 days), participants (WHO 4), intervention (ivermectin 12 mg daily for 5 days), comparator (placebo) (2) Time point (7 days), participants (WHO 4 to 5 incl. asymptomatic people), intervention (ivermectin 12 mg and 24 mg, single dose), comparator (placebo) (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Viral clearance at 7 days (primary analysis) (C) Bias due to missing outcome data: Viral clearance at 7 days (primary analysis) (D) Bias in measurement of the outcome: Viral clearance at 7 days (primary analysis) (E) Bias in selection of the reported result: Viral clearance at 7 days (primary analysis) (F) Overall bias: Viral clearance at 7 days (primary analysis) (1) Time point (7 days), participants (WHO 4), intervention (ivermectin 12 mg daily for 5 days), comparator (placebo) (2) Time point (6 days), participants (WHO 4 to 5), intervention (ivermectin 12 mg daily for 2 days), comparator (placebo) (3) Time point (7 days), participants (WHO 4 to 5 incl, asymptomatic people), intervention (ivermectin 12 mg and 24 mg, single dose), comparator (placebo) (4) Time point (7 days), participants (unclear, min. WHO 4, 20% WHO 5), intervention (ivermectin 0.1 mg/kg, 0.2 mg/kg, and 0.4 mg/kg over 72 hours), comparator (standard of care) (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Viral clearance at 7 days (secondary analysis) (C) Bias due to missing outcome data: Viral clearance at 7 days (secondary analysis) (D) Bias in measurement of the outcome: Viral clearance at 7 days (secondary analysis) (E) Bias in selection of the reported result: Viral clearance at 7 days (secondary analysis) (F) Overall bias: Viral clearance at 7 days (secondary analysis) Analysis 1.15. Comparison 1: Ivermectin compared to placebo or standard of care for people with moderateto-severe COVID-19 treated in the inpatient setting, Outcome 15: Viral clearance at 14 days (primary analysis) Cochrane Database of Systematic Reviews Analysis 1.16. Comparison 1: Ivermectin compared to placebo or standard of care for people with moderateto-severe COVID-19 treated in the inpatient setting, Outcome 16: Viral clearance at 14 days (secondary analysis) Study or Subgroup 1.16.1 Moderate to severe disease (WHO 4 to 9) Ahmed 2020 (1) Okumuş 2021 (2) Subtotal (95% CI) Total events: Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 1 (P = 0.76); I² = 0% Test for overall effect: Z = 2.99 (P = 0.003) Total events: Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 1 (P = 0.76); I² = 0% Test for overall effect: Z = 2.99 (P = 0.003) Test for subgroup differences: Not applicable (1) Time point (28 days), participants (WHO 2 to 3), intervention ( ivermectin 0.4 mg/kg, single dose), comparator (placebo) (2) Time point (21 days), participants (WHO 2 to 5, < 1% participants at WHO 4 and 5), intervention (ivermectin 0.3 mg/kg daily for 5 days), comparator (placebo) (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: All-cause mortality up to 28 days (primary analysis) (C) Bias due to missing outcome data: All-cause mortality up to 28 days (primary analysis) (D) Bias in measurement of the outcome: All-cause mortality up to 28 days (primary analysis) (E) Bias in selection of the reported result: All-cause mortality up to 28 days (primary analysis) (F) Overall bias: All-cause mortality up to 28 days (primary analysis) (1) Time point (15 days), participants (WHO 2 to 5, < 1% participants at WHO 4 and 5), intervention (ivermectin 0.3 mg/kg daily for 5 days), comparator (placebo) Risk of bias legend (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Symptom resolution -number of participants with symptoms resolved up to 14 days (primary analysis) (C) Bias due to missing outcome data: Symptom resolution -number of participants with symptoms resolved up to 14 days (primary analysis) (D) Bias in measurement of the outcome: Symptom resolution -number of participants with symptoms resolved up to 14 days (primary analysis) (E) Bias in selection of the reported result: Symptom resolution -number of participants with symptoms resolved up to 14 days (primary analysis) (F) Overall bias: Symptom resolution -number of participants with symptoms resolved up to 14 days (primary analysis) Analysis 2.5. Comparison 2: Ivermectin compared to placebo or standard of care for people with mild COVID-19 treated in the outpatient setting, Outcome 5: Duration to symptom resolution (secondary analysis) (1) Follow-up until symptom resolution, participants (WHO 2 to 3), intervention (ivermectin 0.2 mg/kg, single dose), comparator (standard of care) Risk of bias legend (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Duration to symptom resolution (secondary analysis) (C) Bias due to missing outcome data: Duration to symptom resolution (secondary analysis) (D) Bias in measurement of the outcome: Duration to symptom resolution (secondary analysis) (E) Bias in selection of the reported result: Duration to symptom resolution (secondary analysis) (F) Overall bias: Duration to symptom resolution (secondary analysis) Cochrane Database of Systematic Reviews Analysis 2.6. Comparison 2: Ivermectin compared to placebo or standard of care for people with mild COVID-19 treated in the outpatient setting, Outcome 6: Any adverse events within 28 days (primary analysis) Chaccour 2021 (1) López-Medina 2021 (2) Total (95% CI) Total events: Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0% Test for overall effect: Z = 1.05 (P = 0.29) Test for subgroup differences: Not applicable (1) Time point (28 days), participants (WHO 2 to 3), intervention (ivermectin 0.4 mg/kg, single dose), comparator (placebo) (2) Time point (21 days), participants (WHO 2 to 5, < 1% participants at WHO 4 and 5), intervention (ivermectin 0.3 mg/kg daily for 5 days), comparator (placebo) Risk of bias legend (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Any adverse events within 28 days (primary analysis) (C) Bias due to missing outcome data: Any adverse events within 28 days (primary analysis) (D) Bias in measurement of the outcome: Any adverse events within 28 days (primary analysis) (E) Bias in selection of the reported result: Any adverse events within 28 days (primary analysis) (F) Overall bias: Any adverse events within 28 days (primary analysis) Analysis 2.7. Comparison 2: Ivermectin compared to placebo or standard of care for people with mild COVID-19 treated in the outpatient setting, Outcome 7: Serious adverse events within 28 days (primary analysis) (1) Time point (28 days), participants (WHO 2 to 3), intervention (ivermectin 0.4 mg/kg, single dose), comparator (placebo) (2) Time point (21 days), participants (WHO 2 to 5 , < 1% participants at WHO 4 and 5), intervention (ivermectin 0.3 mg/kg daily for 5 days), comparator (placebo) Risk of bias legend (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Serious adverse events within 28 days (primary analysis) (C) Bias due to missing outcome data: Serious adverse events within 28 days (primary analysis) (D) Bias in measurement of the outcome: Serious adverse events within 28 days (primary analysis) (E) Bias in selection of the reported result: Serious adverse events within 28 days (primary analysis) (F) Overall bias: Serious adverse events within 28 days (primary analysis) (1) Measured by E-gene clearance, time point (7 days), participants (WHO 2 to 3), intervention (ivermectin 0.4 mg/kg, single dose), comparator (placebo) Risk of bias legend (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Viral clearance at 7 days (primary analysis) (C) Bias due to missing outcome data: Viral clearance at 7 days (primary analysis) (D) Bias in measurement of the outcome: Viral clearance at 7 days (primary analysis) (E) Bias in selection of the reported result: Viral clearance at 7 days (primary analysis) (F) Overall bias: Viral clearance at 7 days (primary analysis) Analysis 2.9. Comparison 2: Ivermectin compared to placebo or standard of care for people with mild COVID-19 treated in the outpatient setting, Outcome 9: Viral clearance at 14 days (secondary analysis) Podder 2020 (1) Total (95% CI) Total events: Heterogeneity: Not applicable Test for overall effect: Z = 0.60 (P = 0.55) Test for subgroup differences: Not applicable (1) Time point (10 days), participants (WHO 2 to 3), intervention (ivermectin 0.2 mg/kg, single dose), comparator (standard of care) Risk of bias legend (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: Viral clearance at 14 days (secondary analysis) (C) Bias due to missing outcome data: Viral clearance at 14 days (secondary analysis) (D) Bias in measurement of the outcome: Viral clearance at 14 days (secondary analysis) (E) Bias in selection of the reported result: Viral clearance at 14 days (secondary analysis) (F) Overall bias: Viral clearance at 14 days (secondary analysis) Risk of bias legend (A) Bias arising from the randomization process (B) Bias due to deviations from intended interventions: All-cause mortality up to 28 days (primary analysis) (C) Bias due to missing outcome data: All-cause mortality up to 28 days (primary analysis) (D) Bias in measurement of the outcome: All-cause mortality up to 28 days (primary analysis) (E) Bias in selection of the reported result: All-cause mortality up to 28 days (primary analysis) (F) Overall bias: All-cause mortality up to 28 days (primary analysis) Search string: ivermectin* OR stromectol* OR mectizan* OR "MK 933" OR MK933 OR eqvalan* OR soolantra* OR sklice* OR stromectal* OR ivomec* Study characteristics: 1) "Intervention assignment": "Randomised" OR 2) "Study type": "Interventional" AND "Study design": "Parallel/Crossover" AND "Unclear" = 119 references #1. TI=(ivermectin* OR stromectol* OR mectizan* OR "MK 933" OR MK933 OR eqvalan* OR soolantra* OR sklice* OR stromectal* OR ivomec*) OR AB=(ivermectin* OR stromectol* OR mectizan* OR "MK 933" OR MK933 OR eqvalan* OR soolantra* OR sklice* OR stromectal* OR ivomec*) #2. TI=(COVID OR COVID19 OR "SARS-CoV-2" OR "SARS-CoV2" OR SARSCoV2 OR"SARSCoV-2" OR "SARS coronavirus 2" OR "2019 nCoV" OR "2019nCoV" OR "2019-novel CoV" OR "nCov 2019" OR "nCov 19" OR "severe acute respiratory syndrome coronavirus 2" OR "novel coronavirus disease" OR "novel corona virus disease" OR "corona virus disease 2019" OR "coronavirus disease 2019" OR "novel coronavirus pneumonia" OR "novel corona virus pneumonia" OR "severe acute respiratory syndrome coronavirus 2") OR AB=(COVID OR COVID19 OR "SARS-CoV-2" OR "SARS-CoV2" OR SARSCoV2 OR"SARSCoV-2" OR "SARS coronavirus 2" OR "2019 nCoV" OR "2019nCoV" OR "2019-novel CoV" OR "nCov 2019" OR "nCov 19" OR "severe acute respiratory syndrome coronavirus 2" OR "novel coronavirus disease" OR "novel corona virus disease" OR "corona virus disease 2019" OR "coronavirus disease 2019" OR "novel coronavirus pneumonia" OR "novel corona virus pneumonia" OR "severe acute respiratory syndrome coronavirus 2") #3. #1 AND #2 Indexes=SCI-EXPANDED, ESCI Timespan=2020-2021 = 160 references medRxiv (Advanced search) for abstract or title "ivermectin AND randomized" (match all words) for abstract or title "ivermectin AND randomised" (match all words) MP: conception of the review; design of the review; search and selection of studies for inclusion in the review; collection of data for the review; assessment of the risk of bias in the included studies; analysis of data; assessment of the certainty in the body of evidence MS: conception of the review; design of the review; interpretation of data; writing and proofreading of the review. MIM: search strategy design and writing of the review SG: interpretation of data; writing and proofreading of the review PK: conception of the review; design of the review SW: conception of the review; design of the review; co-ordination of the review; search and selection of studies for inclusion in the review; collection of data for the review SW: is funded by the Federal Ministry of Education and Research • Inclusion criteria * Healthy people exposed directly and constantly to people with COVID-19 (whose disease is confirmed by RT-PCR test and low-to-moderate severity (Grade < 3). People with SpO 2 > 94% who fit outpatient protocol) * Having consent for participating in study • Exclusion criteria * Pregnant or breastfeeding women * People with a certain central nervous system disease * People with an uncontrolled disease (asthma, COPD, cardiovascular disease, diabetes, kidney or liver dysfunction, cancer, hepatitis, AIDS, immunodeficiency) * People receiving immunosuppressive drugs * People receiving any P-450 or P-gp blockers or any medication interacting with ivermectin * People receiving antiviral therapy * People receiving any corticosteroid (inhaled, oral, or injection) * Any known sensitivity to ivermectin or starch or history of lactose intolerability (for placebo) * People with positive SARS-CoV-2-specific antibody • Details of intervention for relevant arms * Type and dose: ivermectin 0.2 mg/kg, single dose * Route of administration: oral • Treatment details of control group * Placebo • Concomitant therapy: index patient receives placebo in both relevant arms Outcomes• Primary study outcome * Percentage of participants in family members * Duration of illness * Severity of disease • Relevant review outcomes planned * Proportion of deaths at 28 days * Considering the drug adverse effects during the study * Duration of the illness with recheck of RT-PCR at 3 and 7 days • Additional study outcomes * Considering the changes in serum antibody level of IgA and IgM * Proportion of subjects needing oxygen use within 28 days * Proportion of subjects needing high-flow oxygen therapy or non-invasive ventilation within 28 days * Proportion of hospitalizations at 28 days * Proportion of mechanical ventilation use at 28 days * Duration of hospitalization within 28 days Cochrane Database of Systematic Reviews Participants• Inclusion criteria * Bangladeshi aged 18-65 years admitted to any of the study hospitals * Men or women * At the enrolment having ≥ 1 of the following symptoms: temperature ≥ 37.5 °C, cough, or sore throat * SpO 2 > 94% * Duration of illness ≤ 7 days * No oxygen support on enrolment * Capable of swallowing oral medication * PCR positive for SARS-CoV-2 virus * Participant properly informed about the study and agreed to sign the informed consent form • Exclusion criteria * Allergy to ivermectin or doxycycline; or other contraindications to any of the study medications * History of chronic heart disease (ischaemic heart disease, heart failure, documented cardiomyopathy, etc.) * History of chronic liver disease (alanine transaminase value > 3 times normal value) * History of chronic kidney disease (creatinine for men > 1.3 mg/dL or > 115 µmol/L and for women > 1. □ Participants taking medications that may interfere with the study medication such as anticoagulants □ Inability to take oral medication □ Severe liver disorders (Child-Pugh C) □ Impairment of severe renal function (with glomerular filtration rate ≤ 30 mL/minute/1.73 m 2 ) or requiring dialysis □ Participants with coagulation disorders □ Participants with severe neurological or mental impairment □ Pregnant or lactating women □ Unable to consent to the study protocol □ People with known hypersensitivity to ivermectin □ People who have been treated in any other study in the previous 30 days □ Concomitant administration of enzyme inducers (such as carbamazepine) that could affect the effectiveness of the drug and those receiving CYP3A4 substrates (such as statins) due to the risk of increased toxicity □ Any other contraindication according to the technical sheet for ivermectin * Substudy prevention □ Participants taking medications that may interfere with study medication □ Inability to take oral medication □ Severe liver disorders (Child-Pugh C) or alcoholism □ Impaired severe renal function (with glomerular filtration rate ≤ 30 mL/minute/1.73 m 2 ) or requiring dialysis □ Participants with coagulation disorders □ Participants with severe neurological or mental impairment □ Pregnant or lactating women □ Unable to consent to study protocol □ People with known hypersensitivity to ivermectin □ People who have been treated in any other study in the previous 30 days □ Concomitant administration of enzyme inducers (such as carbamazepine) that could affect the effectiveness of the drug and those receiving CYP3A4 substrates (such as statins) due to the risk of increased toxicity □ Any other contraindication according to the technical data sheet for Ivermectin • Details of intervention * Type and dose: ivermectin 3 mg, no information on frequency scheme * Route of administration: oral • Treatment details of control group * Placebo • Concomitant therapy: NA • Primary study outcome * Substudy treatment: compare viral clearance in people with SARS-CoV-2 treated with ivermectin and placebo, time point unclear * Substudy prevention: compare contagion rate between home contacts of people with COV-ID-19 receiving prophylaxis with ivermectin and placebo, time point unclear • Relevant review outcomes planned * None Cochrane Database of Systematic Reviews• Exclusion criteria * Duration of symptoms ≥ 10 days AND symptoms clearly getting better * Residents in an aged care facility (hostel or nursing home) or quarantine hotel * Not usually fully independent in activities of daily living and self-care including: washing, toileting, dressing, and dental care * Current residence outside logistical boundaries of the study as defined from time to time during recruitment * Self-reported severe liver disease or cirrhosis, or both * Use of warfarin * Known allergy to Ivermectin * Fit, seizure, or stroke in the last 6 months * Dementia of any type * Head injury requiring medical attention in the last 6 months * Concussion in the last 6 months * Current use of the following medications: verapamil, ciclosporin, cobicistat, ritonavir, ketoconazole, itraconazole, fusidic acid, erythromycin, clarithromycin * Current use or use within the last 3 months of the medication: amiodarone * Psychosocial illness which in the opinion of the investigative team would make successful trial completion (including follow-up data collection) unlikely, for example including: uncontrolled substance use, homelessness, poorly controlled mental state disorder * Inability to communicate in English to the level necessary to provide verbal consent and telephone call follow-up data * Current participation in another clinical drug trial for SARS-CoV-2 • Details of intervention * Type and dose: ivermectin 0.2 mg/kg, single dose with the option of a second dose after 7 days * Route of administration: oral • Treatment details of control group * Placebo • Concomitant therapy: NA • Primary study outcome * Proportions of participants progressing to hospitalization due to SARS-CoV-2 or death at 14 days • Relevant review outcomes planned * Proportions of participants progressing to hospitalization due to SARS-CoV-2 or death at 14 days * Hospitalization without death at 14 days * Proportions of participants progressing to admission to intensive care due to SARS-CoV-2 or death at 14 days * Proportions of participants progressing to requirement for intubation because of SARS-CoV-2 or death at 14 days * Duration of hospitalization of survivors within 14 days * Duration of outpatient symptoms at 14 days * Proportion of participants progressing to death at 28 days • Additional study outcomes * Proportions of participants progressing to hospitalization or death at 7, 21, and 28 days * Proportions of participants presenting to hospital with any of the following: clinical signs of respiratory distress (> 20 breaths per minute) or oximetry desaturation (≤ 94%) (or both), clinical or radiological signs of pneumonia at 7, 14, 21, and 28 days * Proportions of participants progressing to admission to intensive care due to SARS-CoV-2 or death at 7, 21, and 28 days * Proportions of participants progressing to requirement for intubation because of SARS-CoV-2 or death at 7, 21, and 28 days * Duration of hospitalization of survivors within 7, 21, and 28 days and up to 6 months * Duration of outpatient symptoms at 7, 21, and 28 days * Proportion of participants progressing to death at 7, 14, and 21 days and up to 6 months • Primary study outcome * Proportion of participants with a positive SARS-CoV-2 PCR from a nasopharyngeal swab 7 days after treatment • Relevant review outcomes planned * All-cause mortality at 21 days • Additional study outcomes * Mean viral load at baseline and on 4, 7, 14, and 21 days * Proportion of participants with fever and cough at days 4, 7, 14, and 21 days * Proportion of participants with a positive rapid diagnostic test at 21 days * Participants progressing to severe disease or death during the trial * Proportion of drug-related adverse events at 7 days * Seroconversion at 21 days * Levels of IgG, IgM, and IgA up to and at 21 days Cochrane Database of Systematic Reviews surgical sterilization such as vasectomy or intrauterine device, taking oral contraceptive, using condoms * Severe liver damage (AST or ALT at the time of qualification test is > 3 times the upper limit of institutional standard and total bilirubin is > 2 times upper limit of institutional standard value), renal disorder (estimated glomerular filtration rate of eligibility test value ≤ 30 mL/ minute/1.73m 2 ) * Hypersensitivity to ivermectin * History of severe drug allergies such as Stevens-Johnson syndrome, toxic epidermal necrolysis * Received prespecified prohibited medication within the past month (within the past 6 months for biologicals), or those who need to use prespecified prohibited medication during the clinical trial period * Participating in other clinical trials or who have participated in other clinical trials within 30 days before obtaining consent * Person considered unsuitable for this clinical trial by the principal investigator • Inclusion criteria * Age ≥ 18 years * Laboratory-confirmed positive SARS-CoV-2 RT-PCR test within 7 days prior to randomization * Clinical status on the COVID-19 Ordinal Scale 1-3 * Participant (or legally authorized representative) gives written informed consent prior to performing any study procedures * Participant (or legally authorized representative) agree that they will not participate in another COVID-19 trial during this study • Exclusion criteria * Enrolled in a study to investigate a treatment for COVID-19 * Require oxygen use, hospitalization, or mechanical ventilation * Tachycardia (heart rate > 150 beats per minute) or hypotension (systolic/diastolic blood pressure < 90/60 mmHg) * Allergic to the investigational product or similar drugs (or any excipients) * QTcF > 450 msecond * Uncontrolled medical conditions that could compromise participation in the study -uncontrolled hypertension (systolic/diastolic blood pressure > 220/120 mmHg), uncontrolled hypothyroidism (thyroid-stimulating hormone > 10 IU/L), uncontrolled diabetes mellitus (glycosylated haemoglobin > 12%) * ALT or AST > 5 times the upper limit of normal * Estimated glomerular filtration rate < 30 mL/minute or requiring dialysis * Person (or legally authorized representative) unwilling or unable to provide informed consent • Details of intervention * Type and dose □ Intervention 1: ivermectin 0.6 mg/kg, once daily for 5 days □ Intervention 2: ivermectin 1 mg/kg, once daily for 5 days * Route of administration: NR • Treatment details of control group * Placebo with standard of care • Additional study outcomes: * WHO COVID-19 Ordinal Scale for Clinical Improvement at 7 days □ Proportion of participants needing oxygen use within 28 days □ Proportion of participants needing high-flow oxygen therapy or non-invasive ventilation within 28 days □ Proportion of hospitalizations at 28 days □ Proportion of mechanical ventilation use at 28 days □ Duration of hospitalization within 28 days * Time-to-recovery within 28 days * Viral load at 5 days * Positivity rate of RT-PCR SARS-CoV-2 (qualitative analysis) at 5 days * Duration of fatigue, ansomia within 14 days * Proportion of participants needing additional drugs or interventions within 28 days * Proportion of pressors use at 28 days * Proportion of post-COVID mental, physical, and overall symptoms at 30, 60, and 90 days * Duration of new oxygen use within 28 days * Duration of mechanical ventilation within 28 days * Proportion of increased ultrasensitive CRP, erythrocyte sedimentation rate, eosinophils at 1, 3, and 7 days * Proportion of increased D-dimer at 7 days * Disease duration • Inclusion criteria * Age > 18 years with the ability to provide free and informed consent * Acute influenza-like symptoms < 7 days * At least 1 enhancement factor □ Age > 50 years □ Diabetes mellitus requiring oral medication or insulin □ Systemic arterial hypertension requiring at least 1 oral medication for blood pressure control □ Known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) □ Symptomatic lung disease (emphysema, chronic bronchitis) □ People with symptomatic asthma requiring chronic use of agents for control of symptoms □ Smoking □ Obesity, defined as body mass index > 30 kg /m 2 bodyweight □ Received transplant □ Stage IV chronic kidney disease or receiving dialysis □ Immunosuppressed/using corticosteroid therapy (equivalent to prednisone ≥ 10 mg/day) or immunosuppressive therapy, or both) □ History of cancer in the last 5 years or undergoing treatment of a current cancer □ Chronic renal disease KDIGO (Kidney Disease Improving Global Outcomes) IV or end-stage renal disease on chronic ambulatory renal replacement therapy * Positive rapid test for SARS-CoV-2 antigen performed on occasion of the screening or with a positive SARS-CoV-2 diagnostic test within 7 days of the onset of symptoms. * Willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research Cochrane Database of Systematic Reviews• Exclusion criteria * Negative SARS-CoV-2 test * Influenza-like symptom onset ≥ 8 days * People with COVID-19 being referred for hospitalization * History of SARS-CoV-2 vaccine shot * Acute respiratory conditions due to other causes * Dyspnoea secondary to other acute and chronic respiratory causes or infections (e.g. decompensated COPD, acute bronchitis, pneumonia, primary pulmonary arterial hypertension) * Acute influenza-like condition presenting with ≥ 1 of the criteria below:□ Respiratory rate > 28 breaths/minute □ SaO 2 < 90% or < 93% in nasal oxygen therapy at 10 L/minute □ PaO 2 /FIO 2 < 300 mmHg * Using serotonin reception inhibitors (donepezil, sertraline) * Use of the following medications in the last 14 days □ Monoamine oxide inhibitors: phenelzine, tranylcypromine, selegiline, isocarboxazide, moclobemide □ Use of iodinated contrasts during start of treatment through D14 □ Use of antiretroviral agents * Severe psychiatric disorders or major uncontrolled depression or controlled with any of the prohibited drugs above * Pregnant or breastfeeding women * History of severe ventricular cardiac arrhythmia (ventricular tachycardia, people with ventricular fibrillation recovered) or long QT syndrome * History of diabetic ketoacidosis or clinical condition that maintains persistent acidosis * Surgical procedure or use of contrast designed to occur during treatment or up to 4 days after the last dose of the study medication * Current daily or uncontrolled alcoholism * History of seizures in the last month or uncontrolled medical condition * Clinical history of liver cirrhosis or Child-Pugh C classification * Known severe degenerative neurological diseases or serious mental disorders * Inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol * Known hypersensitivity or intolerance to fluvoxamine, ivermectin or metformin * Inability to take oral or sublingual medications * Inability to follow protocol-related procedures • Details of intervention for relevant arms * Type and dose: ivermectin 6 mg, once daily for 3 days * Route of administration: oral • Treatment details of control group * Placebo • Concomitant therapy: NA • Primary study outcome * Evaluation of emergency department visits and observation unit stay > 6 hours * Hospitalization due to COVID-19 progression within 28 days • Relevant review outcomes planned * Adverse events at 28 days • Exclusion criteria * Severity criteria defined in the Coronavirus Disease Epidemiological and Laboratory Surveillance Guide (Version 3/11/2020) * Pregnant or breastfeeding women * Women of childbearing age and without commitment to use contraceptive methods during the study * Inability to complete the study * Current treatment with drugs known to interact with ivermectin * Known intolerance to ivermectin, its derivate, or any of its excipients * Known Child-Pugh C liver disease * Prior ivermectin consumption in the 10 days prior to study entry Participants • Inclusion criteria * Confirmed case of COVID-19 in national reference hospitals -COVID sentinel hospitals. * Men and women aged 18-75 years inclusive * Supply of signed and dated informed consent form * Declared availability to comply with all study procedures and availability for duration of the study * In good general health with mild or moderate symptoms during the first week of disease evolution (onset of symptoms maximum 7 days before recruitment) * Ability to take oral medications and be willing to adhere to the medication consumption regimen prescribed in the study * Must, in the opinion of the principal investigator, be able to comply with all requirements of the clinical trial (including home monitoring during isolation) * Able and willing to comply with the requirements of the protocol. Voluntarily signed informed consent obtained prior to any proceeding related to the trial • Exclusion criteria * History of ivermectin allergy * Hypersensitivity to any component of ivermectin or the excipients of the brand to be used * COVID-19 pneumonia: diagnosed by the treating physician or identified on a chest x-ray * Fever or cough present > 48 hours * IgG positive against SARS-CoV-2 by a rapid diagnostic test * Recent travel history to Loa loa endemic countries (Angola, Cameroon, Central African Republic, Chad, the Democratic Republic of the Congo, Ethiopia, Equatorial Guinea, Gabon, Republic of the Congo, Nigeria, and Sudan) * Current use of quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, ciclosporin, tacrolimus, indinavir, ritonavir, or cobicistat * Use of critical drugs such as warfarin • Details of intervention * Type and dose: ivermectin 0.6 mg/kg, single dose * Route of administration: oral • Treatment details of control group * Placebo • Concomitant therapy: NA • Primary study outcome * Evolution of viral load within 3 days * Clinical remission at 28 days • Relevant review outcomes planned * Clinical signs of toxicity or adverse effects within 28 days * Need for supplemental oxygen at 28 days * Need for mechanical ventilation at 21 days • Additional study outcomes * Hospital stay within 3 months Participants • Inclusion criteria * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Men or women, aged 18-85 years * Close contacts (6 m with no personal protective equipment) to confirmed RT-PCR-positive individual * Ability to take oral medication and be willing to adhere to the study regimen * Women of reproductive potential: negative pregnancy test and last menstrual period date * Agreement to adhere to Lifestyle Considerations throughout study duration Cochrane Library Trusted evidence. Informed decisions. Better health. • Exclusion criteria * Current use of cytochrome P4 enzyme inducers such as azole group of oral antifungal medication (ketoconazole, itraconazole), warfarin * Non-exposure to people with COVID-19 * Refuse to give informed consent * Pregnant and lactating women * Known hypersensitivity to ivermectin * Have had treatment with any investigational drug within 2 weeks prior to randomization * Children, stigmatized population, institutionalized people * Previously diagnosed and recovered from COVID-19 * Severely ill people such as those on ventilators, hepatic or renal impairment, or unconscious * People receiving drugs that can have serious interactions with the trial drug including barbiturates (e.g. asphennobarbital, butalbital), benzodiazepines ( A woman will be considered to have no reproductive capacity if she is postmenopausal (≥ 2 years without her menstrual cycles) or if she has undergone surgical sterilization (≥ 1 month before the time of inviting her to participate in this study) * Weight at inclusion > 48 kg * Signed informed consent for participation • Exclusion criteria * Pregnant or breastfeeding women * Known allergy to ivermectin or some of the components of ivermectin tablets or placebo * Current use of home oxygen * That require hospitalization due to COVID-19 at the time of diagnosis or history of hospitalization for COVID-19 * Presence of malabsorptive syndrome * Presence of any other concomitant acute infectious disease * History of severe liver disease, e.g. liver cirrhosis * Need or use of antiviral drugs at the time of admission for another viral pathology other than COVID-19 * Need or use of hydroxychloroquine or chloroquine * Use of ivermectin up to 7 days prior to randomization * Receiving dialysis or required dialysis in the last 2 months or who plan to in the next 2 months * Current participation or in the last 30 days in a research study that has included the administration of a drug The review di ers from the protocol for the following aspects (Popp 2021).1. We introduced 'patients discharged without respiratory deterioration or death at 28 days' that was reported by one study as a new primary outcome in the category 'improvement of clinical status' (inpatient setting) (Gonzalez 2021). This outcome was considered clinically useful. 2. We added the following paragraph to the 'type of participants section' to clarify how we handled studies including a mixed population with confirmed and suspected COVID-19 diagnosis: "If studies included participants with a confirmed or suspected COVID-19 diagnosis, we used only the data for the patient population with confirmed COVID-19 diagnosis. In cases, where data were not reported separately for people with confirmed or suspected COVID-19 diagnosis, we excluded the study." We considered this specification clinically relevant since it would be a loss of evidence to exclude data on people positive for SARS-CoV-2. 3. Since we found no eligible trials that reported on 'serious adverse events' and 'adverse events' in an outpatient setting within 14 days, we changed the eligible time point for both of those outcomes from 'within 14 days' to 'within 28 days,' which two studies provided and was considered clinically useful (Chaccour 2021; López-Medina 2021). 4. We added a paragraph to the methods section 'Methods for future updates.' The living systematic review approach was included in this review from the beginning as part of the CEOsys project.